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ABSTRACT
SIMPLE MICROMETHODS FOR DETERMINATION OF ISOFORMS 
OF APOLIPOPROTEINS
by
BOUCHRA HARAKE
Apolipoproteins E and C (apo E, apo C) are major components of 
triglyceride-rich lipoprotein, very-low-density lipoprotein (VLDL) 
and chylomicrons. Polymorphysim of apo E accounts for a substantial 
amount of the genetically determined variance of cholesterol levels 
in the population, and is an important factor in the development of 
type III hyperlipidemia. Determination of the isoforms of apo C is 
used to study apo C distribution in hypertriglyceridemic subjects 
and identify apo CII deficiency.
A simple and rapid isoelectric focusing method for phenotyping 
apolipoprotein E and quantifying apo C was developed. The very-low- 
density lipoprotein was isolated within 3 h from 100 fiL of EDTA 
plasma using a Beckman Airfuge® ultracentrifuge.
Delipidated VLDL used for phenotyping apo E and quantifying 
apo C was applied to an ultrathin flat acrylamide gel and focused 
using a Bio-Rad* Mini lEP Cell for 1.5 h at a maximum of 500 V. Apo 
E was resolved into three major bands, apo E* (pi 6.02 ± 0.04), apo 
Ej (pi 5.88 ± 0.03), and apo E^  (pi 5.72 ± 0.03). These bands were 
identified by cysteamine treatment and by immunofixation 
isoelectric focusing using goat antibody to apo E.
Apo C isoforms of VLDL were resolved into four bands, apo 
Clllo (pi 4.97 ± 0.03), apo CII (pi 4,84 ± 0.02), apo CIII^ (pi 4.75
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
± 0.02), and apo CIII, (pi 4.57 ± 0.03). The method demonstrated 
within-run and between-run CV's of 2.7% to 11.9% and 4.4% to 12.2%, 
respectively. The relative percentage of C apoproteins and the 
ratio of CII to Clll found in VLDL from plasma of normal, chronic 
renal failure, and hyperlipidémie subjects agreed with previously 
published data.
Polymorphysim of apolipoprotein AI and All were easily 
investigated in plasma by a simple method involving a 30-min 
incubation of 5 (2h of plasma with Tris-HCl buffer containing urea, 
dithiothreitol,and Nonidet P-40. Diluted plasma samples (2 pL) were 
applied on the polyacrylamide gel mixed with an ampholyte of pi 
range of 4-6., followed by isoelectric focusing as described for 
apo E and apo C. The identity of the different apolipoproteins, 
after isoelectric focusing, was verified by immunofixation and/or 
Western blotting technique using a monospecific antibody to apo AI 
or apo All.
In addition, high-density lipoprotein (HDL) was used as a standard 
for apo AI variants. Employing this technique, apo AI was resolved 
into one major band (apo AIq, pi 5.54 ± 0.02) and four minor bands. 
Apo All isoproteins were focused as one major band (apo AIIo, pi 
4.87 ± 0.01) and two minor bands.
The present technique has several definite advantages over the 
previous methods, in that the required sample volume was markedly 
reduced from 5 mL to 100 fih making the technique suitable for 
pediatric use. Isolation of VLDL, isoelectric focusing and staining 
can be accomplished in one day compared to one week with previously 
reported procedures.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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CHAPTER I 
INTRODUCTION
I .1 Lipoproteins
Lipid transport in plasma is facilitated by lipoprotein 
particles. Hydrophobic lipids (triacyglycerol and cholesteryl 
esters) are virtually completely insoluble in water; they are 
solubilized for transport in plasma by incorporation into 
lipoproteins. Plasma lipoproteins are generally spherical 
particles, of which the surface layer is composed of 
phospholipids with fatty acids oriented towards the center of 
the particle (1). Embedded within this surface phospholipid 
layer are molecules of cholesterol and proteins, known as 
apolipoproteins. Cholesteryl ester and triglyceride molecules 
form the core of lipoprotein particles (2-5).
Plasma lipoproteins are synthesized mainly by the liver 
and the intestine and catabolized by hepatic and extrahepatic 
tissues. Their main, well-defined physiological function is to 
transport dietary and/or endogenously synthesized lipids from 
one organ to another (6 ), although they may also be involved 
in the regulation of other important physiological processes. 
In normal plasma, there are tradionally considered to be four 
lipoprotein classes: chylomicrons; very-low-density
lipoprotein (VLDL); low-density lipoprotein (LDL); and high- 
density lipoprotein (HDL) (Table I). Several subfractions of 
VLDL, LDL, and HDL and a lipoprotein class of density 
intermediate between VLDL and LDL (IDL) have also been
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
TABLE I
CLASSIFICATION, PROPERTIES, AND COMPOSITION OF 
HUMAN SERUM LIPOPROTEINS'
Lipoprotein1 class
Parameter Chylomicron VLDL IDL LDL HDL
Density (g/mL) 0.94 0.94-
1.006
1.006-
1.019
1.019-
1.063
1.063-
1.21
Diameter (nm) >70.0 25.0-
70.0
22.0-
24.0
19.6-
22.7
4-10
Electrophoretic
mobility
Origin Pre-B Broad 6 6 a
Triglyceride 
(% wt.)
80-95 45-65 30 4-8 2-7
Phospholipid 
(% wt.)
3—6 15-20 25 18-27 26-32
Free cholesterol 
(% wt.)
1-3 4-8 8 6—8 3-5
Esterified 
cholesterol 
(% wt.)
2-4 16-22 22 45-50 15-20
Proteins (% wt.) 1-2 6—10 15 18-22 45-55
Major
apo 1 ipoproteins
A-I,A-IV 
B,Cl,CIII
, B ,E ,Cl, 
,E CII,CIII
B B A-1
A-II,E
Minor
apolipoprotein
A-II,CII A-I,A-II 
A-IV
E Cl,CII, 
CIII,E
Cl,CII, 
CIII,D,
V
Synthesis Intestine Liver, 
intestine
Intra- Intra- intest- 
vascular vascular ine,
liver
• Modified from Herbert et ai. (4).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3described. Other classifications as based on paper 
electrophoresis in which LDL, VLDL, and HDL were B- 
lipoproteins, pre-B-lipoproteins, and cr-lipoproteins, 
respectively (4).
Lipoproteins interact with enzymes (e.g., lecthin: 
cholesterol acyltransferase (LCAT), or lipases), with lipid 
transfer proteins, or receptors on cell surfaces. The 
composition of a lipoprotein class depends upon the results of 
these kinds of interactions. The summary of classification, 
properties, and composition of human serum lipoproteins are 
shown in Table I.
Although only partially understood at the present time, 
lipoprotein metabolism (Scheme 1) is a complex pathway and 
contains the following steps: (1 ) apolipoprotein synthesis
(either liver or intestine, or both); (2 ) intracellular 
apolipoprotein modification; (3) lipoprotein assembly; (4) 
lipoprotein secretion; (5) extracellular apolipoprotein 
modification; (6 ) hydrolysis of lipoprotein triglycerides by 
lipoprotein lipase and hepatic lipase; (7) asterification of 
lipoprotein cholesterol by LCAT; (8 ) enzyme-catalyzed exchange 
and/or transfer of cholesteryl esters and phospholipids; (9) 
exchange and/or transfer of apolipoproteins; (10) reverse 
transport of cholesterol from cells to lipoproteins; (11) 
receptor-mediated catabolism of lipoproteins. A schematic 
representation of this pathway is shown in Scheme l (modified 
from Teitz (3)).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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51.2 General Properties of Apolipoproteins
At least five major apolipoproteins have been described 
and labeled A through E (7-9). However, a number of subgroups 
within each major group have been differentiated (Table II). 
The major groupings and their subgroups differ in their 
physiochemical behaviour, in their function, and distribution 
in the various lipoprotein species (10).
Apolipoproteins serve at least three important functions 
in lipoprotein metabolism;
Structural protein for lipoprotein particles. Apo B-lOO and 
apo B-48 are required as structural constituents of 
lipoprotein particles for the secretion of triglyceride-rich 
lipoproteins from the intestine and liver. Defects in the 
structure of apo B or in the assembly of apo B containing 
lipoproteins result in the failure of secretion of intestinal 
and hepatogenous triglyceride-rich lipoproteins. Patients with 
this type of dyslipoproteinemia have abetalipoproteinemia or 
homozygous hypobetalipoproteinemia (4), and HDL are the only 
lipoproteins in their plasma. Apo AI is also believed to be an 
important structural protein for the biosynthesis of HDL. 
Individuals with defects in the apo AI gene have a virtual 
absence of HDL in plasma and are at increased risk for 
developing premature cardiovascular disease (11,12).
Cofactor for enzymes. Apolipoproteins can function as a 
cofactor or activator of enzymes involved in lipid-lipoprotein 
metabolism. Apo CII is required for the enzyme activity of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
PROPERTIES AND
TABLE II 
FUNCTIONS OF
o
APOLIPOPROTEINS
Name Tissue
expression
Number of 
amino acids
Function(s)
Apo AI Liver,
intestine
243 Structural, LCAT activator, 
ligand for HDL receptor
Apo All Liver 77 Structural, hepatic-lipase 
activity enhancer
Apo AIV Intestine, 377 Unknown, possible role in 
fat absorption
Apo(a) Liver Variable Unknown
Apo B-48 Intestine 2152 Structural, secretion of 
chylomicron
Apo B-lOO Liver 4536 Structural, secretion of 
VLDL, ligand for LDL 
receptor
Apo Cl Liver, 
intestine
57 LCAT activator
Apo CII Liver,
intestine
79 Lipoprotein-1ipase 
activator
Apo CIII Liver,
intestine
79 Inhibition of removal of 
triglyceride-rich 
lipoprotein
APO D Liver, 
intestine, 
pancreas, 
kidneys
169 Unknown
Apo E Liver, 
macrophages
299 Receptor mediated 
catabolism of apo E 
containing lipoprotein
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
lipoprotein lipase (EC 3.1.1.34), the enzyme responsible for 
hydrolysis of lipoprotein triglycerides to free fatty acids 
and monoglycerides (13,14). Patients with a deficiency of apo 
Oil have severe hypertriglyceridemia, recurrent bouts of 
pancreatitis, and eruptive xanthomas (15). Apo AI activates 
lecithin;cholesterol acyltransferase (LCAT, EC 2.3.1.43), 
which catalyzes the estérification of cholesterol to 
cholesteryl ester (16).
Receptor interactions> Apolipoproteins also play a pivotal 
role in lipoprotein metabolism, being the ligand on the 
lipoprotein particle that interacts with cellular receptors 
for specific lipoproteins. Apo B-lOO and apo E interact with 
the LDL receptor to initiate absorptive endocytosis followed 
by the catabolism of LDL (17,18). Apo AI has been proposed to 
interact with a putative HDL receptor to facilitate the 
removal of cholesterol from peripheral cells for transport 
back to the liver (19-21). The well-established properties and 
functions of the individual apolipoproteins are summarized in 
Table II.
1.3. ADoliDOProtein E
Apolipoprotein (apo) E, initially termed "arginine-rich 
apoprotein", was first identified as a lipoprotein constituent 
of VLDL in 1973 by Shore and Shore (22) and was extensively 
characterized in several animal species after it was realized 
that dietary cholesterol altered apo E distribution in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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species studied (23). In human plasma, apo E is a constituent 
of liver-synthesized VLDL, which functions primarily in the 
transport of triglyceride from the liver to peripheral tissue. 
Apo E is also associated with HDL, which participates in 
cholesterol redistribution among cells. In addition, apo E 
becomes a major protein constituent of intestinally 
synthesized chylomicrons, which transport dietary triglyceride 
and cholesterol. Apo E is equally distributed between VLDL and 
HDL in plasma that is devoid of chylomicrons (24). The normal 
plasma concentration of this protein is 5 mg/dL (25).
Human apo E is synthesized in a variety of tissues as a 
preprotein 317 amino acids in length (26,27). The preprotein 
undergoes intracellular proteolysis, glycosylation, and 
extracellular desialylation, resulting in a single polypeptide 
chain with molecular weight of 34,145 (28,29). The amino acid 
sequence as well as the mRNA nucleotide sequence of apo E are 
known for several species (29-31). The human apo E gene has 
been isolated, characterized, and mapped to chromosome 19, as 
have the genes for apo Cl, apo CXI, and the LDL receptor (31- 
35), but apparently these genes are not closely linked to each 
other (36). Apo E can bind to the LDL (apo B/E) receptor, as 
well as the apo E receptor, and is therefore an important 
mediator in triglyceride-rich lipoprotein catabolism (23,37- 
50). Apo E/E receptor activity is regulated by dietary factors 
and decreases with age, whereas apo E receptor activity does
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of the mutants using several biochemical approaches has 
localized the receptor binding domain of apo E to an arginine- 
and lysine-rich region in the middle of the apo E molecule (in 
the vicinity of residues 140 to 160) (51-55).
1.3.1. Polvmorphism of apo E
The polymorphic nature of apo E was established by 
Utermann et ai. (43,56) using isoelectric focusing, and 
further clarified by Zannis and Breslow (41) using two- 
dimensional electrophoresis. The three major isoforms of apo 
E, referred to as apo E,, Ej, and E«, are products of three 
alleles (e,, e,, ej at a single gene locus. Three homozygous 
phenotypes (apo E^ /z, E3/3, and E,,,) and three heterozygous
phenotypes (apo E3/3, E«/j, and E./a) arise from the expression 
of any two of the three alleles. The most common phenotype is 
apo E3/3 and the most common allele is e,; therefore, apo Ej is 
considered to be the parent form of the protein, and apo E* 
and Ea are variants. Apolipoprotein Ej is the most common form 
of apo E associated with type III hyperlipoproteinemia and is 
defective in receptor binding (25, 37). Apolipoprotein E«
displays normal binding but is associated with elevated plasma 
cholesterol and LDL (17).
The molecular basis for apo E polymorphism was elucidated 
by analysis of the amino acid sequence of the three isoforms 
(29). Amino acid substitutions accounted for the differences 
among apo E«, E,, and E,. Apolipoprotein E, differs from apo E,
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in that in apo E, arginine is substituted for the normally 
occurring cysteine at amino acid residue 112. Apo Ej differs 
from apo E, at residue 158, where cysteine is substituted for 
the normally occurring arginine. The charge differences among 
the three isoforms detected by isoelectric focusing is 
explained by the single amino acid substitutions. A secondary 
form of apo E polymorphism is explained by posttranslational 
glycosylation (42). The glycosylated (sialylated) isoforms 
arise from the attachment of a carbohydrate moiety, which is 
variably sialylated, at a single site in apo E (threonine 
residue 194) (57).
1 .3 .2 . Type III hyperlipoproteinemia
Familial type III hyperlipoproteinemia (HLP), also called 
familial dysbetalipoproteinemia or broad B, or floating S, 
disease, is characterized by premature atherosclerosis, 
xanthomas, elevated plasma cholesterol and triglyceride 
levels, cholesterol-enriched VLDL and IDL particles, and 
increased plasma apo E level (1, 58-60). The most reliable 
criterion used in the past for diagnosis of this disease was 
an increase in the ratio of VLDL-cholesterol to total 
triglyceride (r > 0.30) and a plasma triglyceride
concentration between 150-1000 mg/dL (1.70-11.30 mmol/L) (60- 
62). The frequency of the disease was estimated to be 0.1- 
0.01% in the North American population (59,63).
Utermann et al. (64) described an apparent apo E« and apo 
Ej isoprotein deficiency in patient with type III HLP. The apo
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E phenotype observed in type III HLP is the result of
structural mutation(s) that change(s) the net charge of apo E 
(40,65-67). The most common variant is apo E^  (Argl58 Cys), 
in which cysteine replaces the normally occurring arginine at 
residue 158 (68,69). The apo E variant associated with type 
III HLP has diminished ability to bind to hepatic lipoprotein 
receptor. This low binding of apo £3,2 to hepatic receptor, is 
responsible for the retarded clearance of lipoproteins 
containing apo Ej from plasma in normal individuals and in 
those with type III HLP (24). The prevalence of apo E 
phenotype E,,; was found to be 91% in populations with type III 
HLP (70,71). Most subjects who are homozygotes for apo Ej do 
not develop type III HLP. Indeed, about 1% of the population 
is homozygous for E^ /i, but at most, only 1 in 50 of these 
appears to develop type III HLP (70). Therefore, phenotyping 
of apo E can be used as a molecular marker for diagnosis of 
type III HLP (72).
1.3.3 Effect of apo E alleles on plasma lioid and lipoprotein 
levels
In addition to the contribution of the apo E phenotype to 
the expression of type III HLP, Utermann at al. (73) observed 
that carriers of the c, allele had lower levels of plasma and 
LDL cholesterol than did those with homozygocity for the e, 
allele (73). These findings suggested that the apo E 
phenotypes may be involved in determining the plasma 
lipoprotein levels in the general population (73). Further
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studies have shown that the effect of apo E genotypes on 
plasma and LDL cholesterol follows the order E,,« = E,,, = E.,]
> E3/3 > E3/3 > E3/2 (17,43,74-78). The E^ ,, genotype is associated 
with decreased plasma apo B levels as compared to E„, and E<., 
genotypes (78,79). No association has been found between the 
apo E genotypes and plasma triglyceride and HDL- cholesterol 
levels (17,43,74,75,77,78). A variety of recent studies with 
hyperlipidémie subjects have shown that homozygocity (80) 
and/or heterozygocity (81-84) for the c, allele is associated 
with hyperlipidemia and hypertriglyceri- demia. Attempts by 
several groups to correlate apo E phenotypes with incidence of 
myocardial infarction (76,85-87) or coronary artery disease 
(76) gave either negative or inconclusive results.
1.3.4. Functions of apo E
Lipoprotein catabolism. Apo E is the ligand for the 
cellular recognition and catabolism of apo E containing 
lipoproteins by the LDL (B/E) receptor (88-94). Since apo E 
can exchange freely among lipoprotein particles (23,95), apo 
E mediates the hepatic catabolism of a variety of lipoproteins 
including chylomicrons, VLDL, and IDL (87-93). Apo E may also 
play some role in the conversion of VLDL remnants to LDL 
(75,96). The availability of apo E on lipoprotein particles 
and the affinity to these particles for the LDL (B/E) or other 
receptor(s) may determine the catabolic fate of these 
particles. This may influence plasma VLDL- and LDL- 
choiesterol levels (75,77,80,81) as well as the plasma apo E
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
13
and apo B levels (78,79),
Redistribution of cholesterol. As mentioned earlier, apo 
E is synthesized by a variety of cells and tissues (44,97,98) 
and is secreted in the interstitial fluid (99,100). 
Cholesterol- loaded cells, such as macrophages, can release 
their cholesterol to acceptors in the interstitial fluid. An 
avid cholesterol acceptor is HDL, especially the phospholipid- 
rich, non-apo E containing HDL. As the HDL becomes cholesterol 
enriched, it acquires apo E. Thus, the cholesterol-rich HDL 
with apo E formed in the interstitial fluid of various tissues 
could transport cholesterol from peripheral tissues to the 
liver and extrahepatic cells, where it is taken up by LDL 
receptors (101,102). This process has been characterized as 
"reverse cholesterol transport" (102). The net effect of the 
formation and catabolism of apo E containing lipoprotein 
particles is redistribution of dietary and newly synthesized 
cholesterol to the various cells and tissues and maintenance 
of cholesterol homeostasis.
Another function of apo E mentioned by Mahley (36) is the 
production and accumulation of apo E in response to nerve 
injury and during the regeneration process. Astrocytes of the 
central nervous system synthesize and secrete apo E, whereas 
other brain glial cells and neurons do not (103,104). In the 
peripheral nervous system, apo E is synthesized by the glial 
cells and nonmyelinated Schwann cells near or around the 
sensory and motor neurons (105). Injury of the central or
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peripheral nervous system is associated with increased apo E 
synthesis (106-110). Further, following injury, monocytes and 
macrophages recruited to the site of injury synthesise and 
secrete apo E (36), The cholesterol produced by the 
degenerated myelin is absorbed by the macrophages and Schwann 
cells and is reutilized later by the regenerated cell (36). 
Apo E containing lipoproteins produced by regenerating nerves 
are taken up by B/E receptors present in the tips of the 
growing axons of nerves (36). LDL (B/E) receptors are also 
expressed in Schwann cells during the remyelination process 
(36). These observations led to the hypothesis that the apo E 
LDL (B/E) receptor interaction may play some essential role in 
nerve regeneration (36, 106-110). It is noteworthy to mention 
that apo E is a major apolipoprotein of cerebrospinal fluid 
(CSF) in humans (99). Apo E exists in the CSF as small 
spherical and discoidal lipoproteins that transport 
cholesterol and phospholipid (36). Since CSF lacks apo B and 
LDL, presumably apo E assumes the major role for lipid 
transport in CSF (36). other functions of apo E are highly 
speculative, such as, the involvement of apo E in 
immunoregulation and modulation of cell growth (36).
1.4. Apolipoprotein C
The C group of apolipoproteins in human plasma are 
designated apolipoprotein Cl, CII, CIIIo, CIIl^ and CIII, 
(111). These are well characterized small molecular weight
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proteins (6-9 kd) that play an important role in the 
metabolism of triglyceride-rich lipoproteins (chylomicrons and 
VLDL).
1.4.1. ApoliPOProtein_Cl
Apo Cl is present mainly in VLDL and HDL. It has been 
sequenced and found to contain 57 residues (112,113) with a 
molecular weight of 6605 (114). Human plasma apo Cl
concentration is in the range of 0.04-0.06 mg/mL (114). In 
vitro apo Cl has been shown to activate LCAT but not as 
efficiently as apo Al (115). The physiological role(s) of apo 
Cl has (have) not been defined. Synthesis occurs mainly in 
liver and to a minor degree in intestine and has not been 
evaluated in other organs. Primary qualitative or quantitative 
abnormalities of human apo Cl have not been reported.
1.4.2. Apolipoprotein CII
Apo CII is a constituent of VLDL and HDL. It consists of 
78 residues (116) with a molecular weight of 9 kd (114). Human 
plasma apo CII concentrations are in the range of 0.03-0.05 
mg/mL. Apo CII has attracted a great deal of attention because 
it activates one of the most important enzymes in plasma lipid 
metabolism, i.e., lipoprotein lipase, which is responsible for 
the hydrolysis of triglyceride in chylomicrons and VLDL. This 
enzyme is normally bound to endothelial cell surfaces but can 
be released by heparin administration resulting in a rapid 
clearance of VLDL triglyceride (117). The physiological 
importance of apo CII in activation lipoprotein lipase has
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
16
been established by the finding of patients with inherited apo 
CII deficiency, who are severely hypertriglyceridemia and have 
a functional lipoprotein lipase deficiency (15). In such 
cases, both the hypertriglyceridemia and lipase deficiency can 
be relieved by an exogenous source of apo CII (114). Studies 
using proteolytic fragments and synthetic peptides of apo CII 
have shown that lipoprotein lipase interacts with the COOH- 
terminal amino acids 56-79 (118-119). This interaction is
enhanced by residues 43-51, which possess phospholipid binding 
activity (120). Synthesis of apo CII is mainly in the liver 
and to minor degree in the intestine.
There have been a number of reports of apo CII variants 
in VLDL in human subjects, some of which are associated with 
hypertriglyceridemia. Connelly et al. (121,122) have reported 
two structural variants of apo CII, denoted CII-Toronto and 
Cll-St.Michael, which do not activate lipoprotein lipase and 
are associated with severe hypertriglyceridemia. Other apo Cll 
variants have been described which also do not activate 
lipoprotein lipase (123,124). Havel at al. (125), and Henzel 
at al. (126) have described a CII variant in a subject of 
African descent that possesses normal lipoprotein activation 
potential in vitro. Recently, Huff at al. (127) have 
identified a variant of apo CII designated as apo CII, in a 
hypertriglyceridemic individual. Apo CII, has normal 
lipoprotein lipase activation potential in vitro and its 
presence does not appear to cause changes in VLDL apo B or
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triglyceride metabolism (127).
1.4.3. Apolipoprotein ClII
Apo c m  is a constituent of VLDL and HDL and comprises 
- 50% of VLDL and 2% of HDL protein (114). Human plasma apo 
c m  concentrations are in the range of 0.12-0.14 mg/mL. It is 
a glycoprotein consisting of 79 amino acid residues. Apo CIII 
exists in three isoforms numbered according to sialic acid 
content which confers different electrophoretic mobility to 
each isoform. CIIIo, CIlIi, CIII,, CIII3 subspecies contain, 
respectively, 0 to 3 mole (s) of sialic acid per mole of 
protein. The functional significance of the degree of 
sialylation is uncertain. Two groups have reported that the 
increase in apo CIIIi with hypertriglyceridemia is more 
pronounced than that with apo CIIIo and apo CIII, (128,129). 
Another group has shown that a high-carbohydrate fat-free diet 
for 7 days leads to an increase of apo CIII* relative to the 
other C peptides in VLDL (130). Huff and Nestel have reported 
that a short-term high-carbohydrate diet leads to a relative 
decrease in apo CIII,, though total apo CIII is increased 
(131), while a high-cholesterol diet increases the proportion 
of apo CIII, (132). The biochemical basis for these changes 
and their effects is unknown.
Apo CIII is believed to be an inhibitor of lipoprotein 
lipase (133,134), and decreases the hepatic uptake of the 
triglyceride-rich lipoproteins and remnants (135,136). Excess 
sialylation of apo CIII, and an increased proportion of apo
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
18
CIIIj to apo CIIIi, may impair the interaction of triglyceride 
-rich lipoprotein with lipoprotein lipase (137,138). A low 
ratio of CII/CIII has been demonstrated in hypertriglyceri­
demic subjects (139). A low CII/CIIJ ratio in triglyceride- 
rich lipoprotein has been shown to inhibit lipoprotein lipase 
in vitro (133), and inhibit the hepatic uptake of these 
lipoproteins by perfused rat liver (140). The ratio of apo CII 
and apo CIII subspecies are abnormal in VLDL isolated from 
patients with severe hypertiglyceridemia or with hypertri­
glyceridemia secondary to chronic renal failure (138). The 
abnormal triglyceride-rich lipoproteins, containing excess apo 
Cllla, were poor substrates for bovine milk lipoprotein lipase 
(137). When the lipoproteins are treated with neuraminidase, 
the proportions of apo CIII isoforms are restored to normal, 
and the lipoproteins interacted normally with lipoprotein 
lipase. A severe reduction in apo CIII; by prolonged 
neuraminidase treatment impaired the ability of the 
lipoproteins to act as a lipoprotein lipase substrate (137, 
138). In vitro tests suggested that apo CIII3 inhibited 
hydrolysis by lipoprotein lipase, but that apo CIIIi may have 
increased the degree of hydrolysis. The above findings 
suggest that the different isoforms of apo CIII have 
identifiable functions with regard to lipolysis, but the 
details are still unclear.
1.5. Apolipoprotein Al
Human apo Al is a major constituent of HDL, with a
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molecular weight of approximately 28,300 (141,142). High-
density lipoprotein particles consist of 50% protein and 50% 
lipid, and apo Al is 70% of HDL protein. High-density 
lipoprotein levels are inversely correlated with 
susceptibility to coronary artery disease, and the same 
association has been demonstrated for apo Al. The plasma level 
of apo Al is 1.0-1.2 mg/mL. Apo Al is initially synthesized as 
a 267-amino acid precursor protein, preproapo Al (143,144). 
The human prepeptide contains 18 amino acids, and the 
propeptide contains 6 amino acids attached to the amino 
terminus of apo Al (143). Preproapo Al undergoes intracellular 
cotranslational cleavage to proapo Al, and proapo Al undergoes 
extracellular conversion to mature apo Al (243 amino acids) in 
plasma by an apparent specific calcium-dependent protease 
(143,145). In man, the primary form of apo Al secreted by the 
cell is proapo AE, and proapo Al is quantitatively converted 
in vivo to a mature apo Al with a residence time of 
approximately 4.5 h (146). Proapo Al accounts for 
approximately 4 % of fasting plasma apo Al (147); however, 
proapo Al is increased in thoracic duct lymph following a meal 
enriched in lipid (148).
Mature apo Al is polymorphic in plasma. Nestruck et al. 
(149) reported that four forms of apo Al could be isolated by 
preparative flat bed isoelectric focusing, and all forms had 
an identical apparent molecular weight and common antigenicity 
to antisera against apo Al. Zannis et al. (150) separated six
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plasma apo AI isoproteins, each of molecular weight of 28,000, 
by two-dimensional gel electrophoresis. These isoproteins were 
differed from each other by one charge unit. The nomenclature 
utilized in this work for apo Al isoforms conforms to the 
nomenclature standardized for proteins separated by two- 
dimensional gel electrophoresis (147). In that system the 
major mature isoform is designated with a zero subscript 
(AIo). Other isoforms of the protein are codified by unit 
charge (- or +) from the major isoform (AIo). Thus, the minor 
mature isoforms of apo Al are denoted apo AI.^ and apo AI_,. 
Proapo Al, which contains two additional positive charges when 
compared to mature apo Al, is located at the apo AI., position 
from apo AIo. Plasma from normal subjects has isoproteins AI„ 
(79%), and AI_i and AI_, (19%) as the major forms of apo Al. 
Isoproteins Al.a and AI.^ form only 2% of the apo Al isoforms 
in normal plasma. Apo Al, as well as other apolipoproteins, 
has extensive alpha-helical structure, with one surface of the 
helix containing hydrophilic amino acid residues and the other 
surface containing hydrophobic residues that can combine with 
lipid (142). Apo Al facilitates the LCAT reaction whereby a 
fatty acid attached to lecithin (the major phospholipid of 
HDL) is transfered to cholesterol to form cholesteryl ester 
and lysolecithin (16). During this process, the free 
cholesterol that is converted to cholesteryl ester migrates 
into the core of HDL. This process is important in the 
maturation of an HDL particle, transforming it from a newly
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formed,nascent, flattened, disc-like particle lacking a 
cholesteryl ester core to a sphere in which the HDL core is 
filled with cholesteryl ester. Apo Al appears to be crucial 
for the formation of HDL particles because in its absence 
virtually no HDL is present (11,12,151). A decreased plasma 
apo Al level has been reported in some studies to be a better 
marker for coronary heart disease (CHD) than HDL-cholesterol 
(152). Apo Al appears to participate in the reverse transport 
of cholesterol from tissues to the liver for excretion (10, 
101).
Apo Al abnormality h  been implicated in lipoprotein
disorders and rare genetic diseases which include Tangier 
disease, familial apo Al and CIII deficiency, apo Al 
deficiency, and fish eye disease (101).
Tancfier disease is an autosomal recessive disorder 
characterized by the near absence of apo Al, apo All, and HDL 
(4, 153). This metabolic disorder is reflected as a rapid 
catabolism of apo Al (Tangier), which differs from normal apo 
Al in molecular weight and amino acid composition. Patients 
afflicted with Tangier disease generally have elevated serum 
triglycerides, low LDL, and absence of HDL. Accumulation of 
cholesterol esters in the reticuloendothelial system and other 
tissues is also characteristic (153). Clinical features 
include enlarged orange-coloured tonsils, splenomegaly, a 
relapsing sensory-motor neuropathy, and a possible development 
of mild corneal opacification (4).
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Apolipoprotein AI and CIII deficiency is a combined apo 
Al and CIII deficiency associated with premature athero­
sclerosis (11,154). The deficiency has been shown to be due to 
a rearrangement in the genes for apo Al and CIII (155), which 
are closely linked on chromosome 11 (156). Clinical features 
of this disorder are palmar xanthomas and mild corneal 
opacification, but no evidence of fat malabsorption (11,101).
Familial apolipoprotein Al deficiency is associated with 
planar xanthomas, marked HDL deficiency, and undetectable 
plasma apo Al (157). The defect has been shown to be due to a 
point mutation within the apo Al gene resulting in lack of apo 
Al gene expression (25, 157-159).
Fish eye disease is charaterized by very low HDL levels, 
severe corneal opacity, visual impairment, and hypertri­
glyceridemia (160,161). The marked decrease in HDL is due to 
a deficiency of alpha-LCAT only (the form of LCAT that 
esterifies HDL free cholesterol) (162).
1.5.1 Ap o Al genetic variation
As mentioned above, apo Al is the principal structural 
protein of HDL. Because of the importance of HDL levels in 
predicting atherosclerosis susceptibility, extensive popul­
ation screening by isoelectric focusing has been undertaken. 
To date, eleven variants of apo Al have been elucidated (Table 
III) (114). These variants have been shown in people who 
appear to be heterozygotes for one normal apo Al structural
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TABLE III
APO AI PROTEIN VARIANTS AND THEIR IMPLICATIONS"
Variant Charge
Difference
Defect Implications Reference
AIm! Innn -1 Argi73-Cys Reduces HDL (163,164)
-1 Lys ,07-^ 0 No activity 
for LCAT
(165,166)
A I n u n a t a r Z A -1 Lysio7-»0 No activity 
for LCAT
(167)
A l M u n a t a r a B -1 Alai5,-Glu (168)
A l o l a a a a n +1 Pro^„-Arg Nc activity 
for LCAT
(165)
A l m j n a t o r S * +1 Aspioj-*Asn (167)
A I x u n a t a r S B +1 Pro,-*Arg (167)
AT +1 PrOj-»His (167)
AIwunataraD +1 Aspa^^Gly (168)
A l K u n » t a r 4 +2 Glu,„^Lys (168)
AlNorway +2 GlUi3.-»Lys (168)
Modified from Breslow (114).
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allele and another allele that specifies a gene product that 
is either one charge unit more acidic or one or two charge 
units more basic than wild type (114). Normal apo Al activates 
LCAT, but AIai.„.„, Bhd have been reported to
be defective in this regard (169).
1.6. Apolipoprotein All
Apo All is the second most abundant protein in HDL and 
has a molecular weight of 17,380. It is composed of two chains 
of 77 amino acid residues each, linked with a disulfide bond 
at residue 6 (169,170). Plasma apo All concentrations are 0.3-
0.5 mg/mL. In vitro apo All has been shown to displace apo Al 
from HDL particles (171,172). Apo All has been reported to 
enhance the activity of hepatic lipase, an enzyme that 
hydrolyses (removes the fatty acids from) phospholipids and 
triglycerides within HDL and VLDL (173). However, the 
physiological role of apo All has not been determined and 
primary qualitative and quantitative abnormalities of human 
apo All have not been reported. Apo All is synthesized in the 
liver and intestine as a 100-amino acid precursor protein, 
preproapo All (174). Preproapo All is cotranslationally 
cleaved to proapo All, which contains a pentapeptide attached 
to mature apo All (174). The concentration of proapo All in 
lymph and plasma is less than 1% of total apo All (174).
Schmitz et al. (175) have shown that apo All isoproteins 
can be separated by isoelectric focusing into the following
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isoforms: apo All; (pi 5,16); apo All, (pi 4.89); apo AIIj (pi 
4.58); and apo All, (pi 4.31). Both the nature of these charge 
modifications and their physiological significance are unknown 
(175).
1.7. Phenotyping of Ap o E and Determination of Apo C. 
Apg- AI,..and Apo .All_lsof.«arm5
Methods for phenotyping apo E have been previously 
described (47,176-185). Some of these methods involve a 
lengthy preparative ultracentrifugation (18 h) to isolate VLDL 
as a source material followed by prolonged isoelectric 
focusing (47,176-178). Other investigators, to increase 
specificity, combined isoelectric focusing with immunoblotting 
using specific anti-apo E antisera (180-182). More recently, 
DMA amplification by the polymerase chain reaction technique, 
has been used to study the apo E distribution (183-185). These 
reported techniques are very laborious and time consuming, and 
require specialized equipment and expertise. This has limited 
the diagnostic use of apo E phenotyping and restricted the 
availability of the test to large reference laboratories.
Methods for separation and determination of apo C 
distribution have been previously described (138, 186-188). As 
for apo E, these methods involve isolation of VLDL by a 
lengthy preparative ultracentrifugation and isoelectric 
focusing using high voltages, and are not applicable for 
routine use in the clinical laboratory.
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Methods to study the polymorphism of apo Al and All 
directly on serum without the need of ultracentrifugation have 
been investigated previously (165, 167). One of these methods 
is a lengthy two-step procedure involving electrophoresis then 
isoelectric focusing (165). The other method (167) involves a 
one-step, 17-h isoelectric focusing procedure,
1.8. Purpose _of the Study
In the light of the above considerations, the purpose of 
the study was to develop simple, rapid, precise, and easily 
performed micromethods for phenotyping apo E, quantifying apo 
CII and CIII in human VLDL, and screening apo Al and All 
isoforms in human plasma.
The aim was to eliminate the drawbacks of other methods 
discussed previously, namely;
1 . large sample volumes;
2 . the lengthy preparative ultracentrifugation to isolate 
the VLDL;
3 . the prolonged isoelectric focusing and extremely high 
voltages ;
4 . the requirements of specialized equipment and
expertise.
The first aim is an important consideration, regarding 
the suitability of the method for pediatric use. The second, 
third, and fourth aims are important from a practical point of 
view, i.e., the reduction of time and cost to run the
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procedure, and to make it applicable for the routine clinical 
laboratory.
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CHAPTER II 
EXPERIMENTAL
II.1 Materials
Neuraminidase (Sialidase; N-acetyl neuraminate 
glycohydrolase; EC 3.2.1.18), grade V, from Clostridium 
perfringens was purchased from Sigma Chemical Company, St. 
Louis, MO 63178. The enzyme activity quoted was that of the 
supplier (1.7 units/ mg solid). Definition of unit: One unit 
will liberate 1.0 final of N-acetyl neuraminic acid per minute 
at pH 5.0 and 37°C, using N-acetyl neuramin-lactose as a 
substrate.
Isoelectric point markers (pi markers) were purchased 
from Sigma Chemical Company, consisted of the following 
proteins: trypsin inhibitor, pi 4.6; 6-lactoglobulin A, pi 
5.1; carbonic anhydrase II, pi 5.4; bovine carbonic anhydrase 
II, pi 5.85; and human carbonic anhydrase, pi 6 .6 .
Very-low density lipoprotein (VLDL) or pre-B lipoprotein 
from human plasma was purchased from Sigma chemical Company. 
Protein concentration as quoted by the supplier was 1 mg/mL.
Low-density lipoprotein (LDL), or 6-lipoprotein from 
human plasma was obtained from Sigma Chemical Company. Protein 
concentration quoted was that of the supplier 5 mg/mL.
2-Mercaptoethylamine (cysteamine, thioethanolamine) 
hydrochloride, Coomassie blue G-250, glycerol, Nonidet P-40, 
Triton X-100, Tween-20, dithiothreitol (DTT), and anti-goat
28
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IgG alkaline phosphatase conjugate were purchased from Sigma 
Chemical Company.
Chloroform, methanol, and diethylether were "Analar" 
grade. Urea "Aristar" grade, cupric sulfate, 5-sulfosalicylic 
acid, and trichloroacetic acid were all obtained from BDH 
Inc., Toronto, ON M8Z 1K5.
Coomassie brilliant blue (CBB) R-250 was from Merck, 
Darmstadt, Germany.
Acrylamide, bis-acrylaraide, ammonium persulfate, 
riboflavin-5'- phosphate (FMN), N,N,N',N'-tetramethylene- 
diaraine (TEMED), silver staining kit, and ampholytes of PI 
range 4-6,and 5-7, were purchased from Bio-Rad Laboratories, 
Richmond, CA 94804.
Lipoprotein electrophoresis kit (Beckman Paragon* 
Electrophoresis System) was obtained from Beckman Instruments, 
Inc., Fullerton, CA 92634.
Goat anti-human apolipoprotein E, and apolipoprotein A-I 
antibody were purchased from Atlantic Antibodies. Stillwater, 
MN 55082.
Goat anti-human apolipoprotein A-I (purified through apo 
A-1 affinity column), and goat anti-human apolipoprotein A-II 
(DEAE purified) for Western blot were obtained from MEDIX 
BIOTECH Inc., 420 Lincoln Center Drive. Foster city, CA 94404.
Nitro blue tétrazolium (NBT) and 5-bromo-4-chloro-3- 
indolyl phosphate (BCIP) substrates were purchased from 
BIO/CAN Scientific Inc., 2368 Dunwin Dr., Mississauga, ON L5L
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1 J 9 .
Low-fat dry milk (Carnation instant skim milk powder) was 
purchased from A & P Supermarket, Windsor,ON N9A 1H8.
Nitrocellulose membrane, BioTrace® NT (nitrocellulose), 
was obtained from Gelman Sciences, 600 South Wagner Road, Ann 
Arbor, MI 48106.
Polyvinylidene difluoride (PVDF) membrane was purchased 
from Millipore Corporation, Bedford, MA 01730.
Reagent water was distilled and passed through a Zenopure 
Laboratory Water System, Mega-90, purchased from Canlab, 
Mississauga, ON L5N 3P1.
Blood specimens. Triglyceride-rich lipoproteins wore 
obtained from fresh sera of fasting patients with type IV 
hyperlipoproteinemia, or normolipideraic subjects during 
routine laboratory testing. Some of the patients had already 
started treatment by dietary therapy. Further blood samples 
were obtained from patients with chronic renal failure , 
attending the renal dialysis unit at the Salvation Army Grace 
Hospital, Windsor, ON. Since the specimens used were left over 
from ordered tests, there was no need to obtain patient 
consent and/or University of Windsor Human Research Ethics 
approval. When collected, the samples were assigned numbers, 
rather than the patients' names, in order to assure patient 
confidentiality.
II.2 Instrumentation
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Airfuge. An air-driven table-top ultracentrifuge 
(Airfuge*) with 18” A-lOO aluminum rotor, rated for 95,000 
rpm, which carries six microliter-size tubes was obtained from 
Beckman Instruments, Inc., Spinco Division, Palo Alto, CA 
94304. The tubes used, Ultraclear®, 5 x 20 mm in size, were 
also obtained from Beckman Instruments, Inc.
Ultracentrifuge. Beckman ultracentrifuge, Model L8-55, with a 
65-TY rotor, rated for 65,000 rpm, was obtained from Beckman 
Instruments, Inc.
A low-spesd table-top centrifuge, Beckman model TJ-6 , 
used to separate plasma, was also obtained from Beckman 
Instruments, Inc.
Isoelectric focusing cell. Bio-Rad's Model 111 Mini IE? 
Cell, containing two graphite electrodes with an inter­
electrode distance of 5 cm, equipped with a casting tray, gel 
support film, and glass plates, was purchased from Bio-Rad 
Laboratories, Richmond, CA 94804.
Power supply. A Titan power supply of 500 V maximum was 
obtained from Helena Laboratories, 1530 Lindbergh Drive, 
Beaumont, TX 77704.
Densitometer. Densitometry was performed using a 
Cliniscan® densitometer/analyzer obtained from Helena 
Laboratories.
Lipoprotein electrophoresis. For lipoprotein electro­
phoresis, the following instruments were purchased from 
Beckman Instruments, Inc.: Paragon® power supply, 200 V
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maximum; Paragon cells; and a Paragon dryer to dry the 
electrophoretic support media.
iîeflection densitometry. Cholesterol (C) and triglyceride 
(TG) determinations were performed on Kodak Ektachem 700 
analyzer, Eastman KodaK Co., Rochester, NY 14650.
Vacutainers. Vacutainers* containing EDTA used for blood 
collection were obtained from Becton Dickinson Canada Inc., 
2464 South Sheridan Way, Mississauga, ON L5J 2M8.
Balances. A Mettler PC 4400 Delta Range electronic 
balance was used for weight above l.O g, and a Mettler H16 
semi-automatic balance was used for weights below one gram. 
Both balances were from Fisher Scientific (Canada), Nepean, ON 
K2E 7L6.
pH meter. pH was measured using a Fisher Accumet® pH 
meter obtained from Fisher Scientific. It was equipped with a 
glass electrode purchased from Graphic Controls, Buffalo, NY 
14240.
Micropipettors. The micropipettors used were Gilson 
Pipetman Models P-200 D and P-1000 D, and SMI (60 nL and 12 
pL) with disposable pipet tips available from Handel 
Scientific Company Ltd., Rockwood, ON NOB 2K0.
Glassware. Disposable borosilicate tubes and all other 
glassware were obtained from Fisher Scientific.
II.3 Reagents
All aqueous solutions were prepared using distilled
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deionized water (Type 1 water).
11.3.1. Sample preparation
Solubilizing buffer. This solution consisted of 50 mmol/L 
Tris-HCl buffer, pH 8.2, containing 6 mol/L urea, and 25 
mmol/L dithiothreitol.
Tris-HCl saline buffer. The buffer was prepared to 
contain 50 mmol/L Tris-Hcl and 150 mmol/L sodium chloride. 
The pH was adjusted to 7.4.
Neuraminidase fsialidase) treatment. Neuraminidase stock 
solution was prepared by dissolving 5 units of neuraminidase 
in one mL of 0.1 mol/L acetate buffer, pH 4.5.
Cysteamine treatment. Cysteamine hydrochloride stock 
solution was prepared to contain 2.9 mM cysteamine 
hydrochloride in 0.1 mol/L Tris-HCl buffer, pH 10,3.
11.3.2. Polyacrylamide ael preparation
Monomer concentrate reagent. This solution consisted of 
24.25 % (w/v) acrylamide, and 0.75 % (w/v) bis-acrylamide 
(N,N'-methylene-bis-acrylamide). The solution was prepared by 
dissolving 24.25 g acrylamide and 0.75 g Bis in water, brought 
to a final volume of 100 mL, and then the solution was 
filtered through a 0.45 filter paper. This solution can be 
stored at 4 *C protected from light, for up to one month.
Riboflavin-5'-phosphate (FMN). 0.1 % (w/v)y This solution 
was prepared by dissolving 50 mg riboflavin-5'-phosphate in 50 
mL water.It can be stored up to one month at 4*0 protected 
from light.
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Ammonium persulfate (10% w/v) solution. Prepared by
dissolving 100 mg of ammonium persulfate in 1.0 mL water. This 
solution was prepared fresh daily.
Glycerol (25 % w/v). This solution was prepared by
dissolving 25 g glycerol in 50 mL water, then diluted to 100
mL of water. It can be stored up to one month at 4°C.
11.3.3. Lipoprotein electrophoresis
Agarose gel. The gel obtained from Beckman contains 0.5% 
agarose, 1 .0% barbital buffer, 0 .1% sodium azide, and non­
reactive ingredients necessary for optimum performance.
B-2 barbital buffer. The buffer was prepared by
dissolving 18.2 g of 5, 5-diethylbarbituric acid in deionized 
water to a total volume of 1.5 L to give a final concentration 
of 10 mmol/L and pH 8.6. This solution was stable at 18"c to 
25“C for 60 days.
Reagent alcohol. This reagent was prepared from absolute 
alcohol to contain 95% alcohol.
Lipoprotein worlcing stain. Sudan black B stain (3 mL of 
7.0% (w/w)) was added to 165 mL reagent alcohol. The solution 
was mixed thoroughly, and then 135 mL of deionized water was 
added with stirring for 5 to 10 min. This solution was stable 
for 7 days when stored at 18“C to 25*C.
Fixative solution. This solution was prepared by mixing 
180 mL of reagent alcohol, 90 mL of deionized water, and 30 mL 
of glacial acetic acid. The solution was stored in a closed 
container at 18"c to 25*C.
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Destaining solution. Reagent alcohol (450 mL) was added 
to 550 mL of deionized water, mixed thorougly, and stored at 
18"C to 25“C.
II.3.4. Staining
11.3.4.1. Coomassie brilliant blue R-250
Fixative solution. This solution was prepared to contain 
4% (w/v) sulfosalicylic acid , 12,5% (w/v) trichloroacetic
acid, and 30% (v/v) methanol.
CBB R-250 stain solution. This solution was prepared to 
contain 27% (v/v) ethanol, 10% (v/v) acetic acid, 0.04% (w/v) 
CBB R-250, and 0.5% (w/v) cupric sulfate. The cupric sulfate 
was dissolved in water before adding the alcohol. The CBB R- 
250 was dissolved in alcohol or added to the solution at the 
end. This solution should be filtered before use.
First destaining solution. This solution was prepared to 
contain 12% (v/v) ethanol, 7% acetic acid, and 0.5% (w/v) 
cupric sulfate, which was dissolved in water before adding the 
alcohol.
Second destaining solution. This solution was prepared to 
contain 25% (v/v) ethanol and 7% (v/v) acetic acid.
11.3.4.2. Coomassie blue G-250 "Quick Stain". This 
solution was prepared to contain 3.5% perchloric acid and 
0.025% (w/v) Coomassie blue G-250.
Intensifying solution. This solution was prepared to 
contain 7% (v/v) acetic acid.
11.3.4.3. Silver stain. The silver stain kit consists of
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the following reagents:
Oxidizer concentrate. The oxidizer concentrate solution 
contained potassium dichromate and nitric acid. This solution 
had a shelf life of more than six months when stored at 4°C. 
Working oxidizer solution was prepared just before use by 
diluting 10 mL of the oxidizer concentrate to 100 mL of water.
Silver reagent concentrate. The concentrated (ten-fold) 
silver nitrate stock solution (Bio-Rad) was stored at 4°C. A 
working solution was prepared just before use by diluting 10 
mL of silver nitrate concentrate to 100 mL of water.
Developer. A dry chemical blend of the developer 
contained sodium carbonate and paraformaldehyde and was stored 
at 4"C. A working solution of developer was prepared by 
dissolving 32 g of developer per liter of distilled water. 
This working solution was stable for one month at 23-25*C.
Fixative solution. The same fixative solution employed 
for CBB R-250 was used.
Second fixative solution. This solution was prepared to 
contain 10% (v/v) ethanol and 5% (v/v) acetic acid.
11.3.5. Immunofixation
Anti-apo E solution. This was prepared by diluting 
goat anti-human apolipoprotein E ten fold with 50 mmol/L Tris- 
HCl saline buffer, pH 7.4.
Anti-apo AI solution was prepared by diluting goat 
anti-human apolipoprotein AI 5 or 6 fold with 50 mmol/L Tris- 
HCl saline buffer, pH 7.4.
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II.3.6, I ïïimunob lotting
Transfer buffer. This solution was made to contain 6.25 
mM Tris-HCl, 250 mM glycine and 20% of methanol, and the pH 
was adjusted to 8.0.
Tris buffer saline Tween (TEST). This solution was made 
to contain 10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween 20, and 
the pH was adjusted to 8.0.
Blocking solution. This solution consisted of 5% low-fat 
powder milk dissolved in TEST.
Alkaline phosphatase (AP) buffer. This solution was made 
to contain 100 mM Tris-HCl, 100 mM NaCl, and 5 mM MgCla, and 
the pH was adjusted to 9.5.
Substrate solution. This solution was made to contain 66 
pL of NET and 33 /iL BCIP in 10 mL of AP buffer.
Goat anti-human apolipoprotein £. This solution was 
prepared to contain 1 in 1000 dilution of anti-apo E in TEST 
buffer.
Goat anti-human apolipoprotein AT. This solution was 
prepared to contain 1 in 1000 anti-apo AX in TBST buffer.
Goat anti-human apolipoprotein All. This solution 
contained 1 in 1000 of anti-apo All in TBST buffer.
XI.4. Procedure
Phenotyping apo E and determination of apo C isoforms 
were performed on delipidated VLDL fractions which were 
isolated using a Beckman Airfuge* ultracenrrifuge.
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Determination of apo AI and apo All isoforms were carried out 
directly on plasma samples without the need for ultracentri­
fugation to isolate the HDL fraction. The orocedures followed 
for isoelectric focusing, fixation, and staining were the 
same for apo E, apo C and apo A.
Identification of apo E and determination of apo AI 
isoforms were carried out using immunofixation and imnuno- 
blotting (Western blot) techniques. Determination of apo All 
isoforms was carried out by Western blot only.
II.4.1. Sample preparation
Blood collection. Blood from fasting normolipidemic and 
hyperlipidémie patients were collected for routine laboratory 
use in Vacutainers containing EDTA. Plasma was separated from 
red blood cells using low-speed centrifugation within 8 h of 
collection, and stored for up to 3 days at 4°C before 
analysis.
Isolation of VLDL by Airfuge. The VLDL fraction was 
isolated from plasma using a Beckman Airfuge® according to the 
method of Strobl and Widhalm (189). In our modification of 
this procedure, VLDL was isolated as follows; 100 /iL of plasma 
were overlayered with 75 nL of 0.15 H NaCl (density, 1.006), 
and centrifuged at 149,000 x g (207 kPa compressed air 
pressure) at 25°C for 3 h. The top 75"/iL fraction was 
collected by aspiration with a micropipettor. Cholesterol and 
triglyceride were determined in the supernate and the results 
were corrected by a factor of 0.75 to give the VLDL-C and
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VLDL-TG concentrations in plasma (189). See II.4.2 for 
cholesterol and triglyceride analysis.
Isolation of VLDL by preparative ultracentrifuge. For 
comparison, VLDL was isolated using a Beckman ultracentrifuge. 
The method used was a modification of Warnick et al. (176). In 
this method, plasma (5 mL) was overlayered with 1.5 mL of 0.15 
M NaCl, and centrifuged at 161,000 x g at 10 °C for 20 h. The 
top fraction of VLDL was isolated by aspiration with a 
micropipettor. Cholesterol and triglyceride were determined in 
the supernate and the results were corrected to the total 5 mL 
plasma used (176). See II.4.2 for cholesterol and triglyceride 
analysis.
Delipidation of VLDL. The procedure utilized was that 
described by Osborne (190) which was based primarily on the 
method of Herbert et al. (191). This is a two-step
delipidation procedure. In the first step , VLDL fraction (75 
/iL) was added to 2 mL of methanol and the mixture was 
vortexed. Cold diethyl ether (5 mL) was added and the mixture 
vortexed again. After standing on ice for 15 to 20 min, the 
mixture was centrifuged at 1500 x g for 5 min, and the
supernatant was removed by aspiration. In the second step, 
diethyl ether (5 mL) was added to the precipitate and the
mixture vortexed and allowed to stand on ice for 15 min,
followed by centrifugation and removal of the supernatant by 
aspiration. The remaining ether was evaporated under a stream 
of nitrogen.
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In some experiments, the 75-^L VLDL fraction was 
dexipidated in a 1.5-mL polypropylene microcentrifuge tube, 
using the same delipidation procedure as described above with 
a smaller volume of reagent (0.3 mL of methanol and 0.9 mL of 
diethyl ether). When isoelectric focusing (lEF) was not 
carried immediately on the delipidated samples, the 
delipidated samples were stored at - 20 °C.
Delipidation of plasma samples. A mixture of chloroform, 
methanol, and ether (4:2:1 v/v) (1 mL) was added to 10 /iL of 
plasma in a 1.5-mL polypropylene microcentrifuge tube, and 
mixed by continuous gentle inversion on a shaker for 30 min at 
room temperature. After centrifugation (5 min at 12 000 x g) 
the supernatant fluid was decanted and 1 mL of ether was added 
for further delipidation for 30 min. After further 
centrifugation and décantation, the protein pellet was allowed 
to air-dry, then either promptly solubilized with solubilizing 
buffer or stored at -20 °C. The delipidated plasma was used 
for phenotyping of apo E and determination of apo AI isoforms 
by Western blotting technique.
Solubilization of the delipidated VLDL. Delipidated VLDL 
samples were solubilized by allowing them to stand in 
solubilizing buffer (50 mmol/L Tris-HCl buffer, pH 8.2, 
containing 6 mol/L urea and 25 mmol/L dithiothreitol) and 
incubated at room temperature for at least 30 min. Because apo 
E is mainly present in the triglyceride-rich lipoproteins, the 
volume of solubilizing buffer used to solubilize the protein
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pellet was varied according to the triglyceride concentration 
of the plasma sample and/or to the type of staining procedure 
carried out. For the more sensitive silver staining procedure 
and the immunofixation procedure, 25 pL of buffer was added 
for each mmol/L of triglyceride in the sample; e.g., if 
triglyceride in the plasma sample is 2 mmol/L, then 50 mmol/L 
of buffer were used to solubilize the VLDL. For CBB R-250 
staining, the pellet was solubilized with 15 to 30 /iL of 
buffer. Nonidet P-40 (a non-ionic detergent) when included in 
the solubilizing buffer was used at a concentration of 0.5% 
v/v.
Solubilization of plasma sample. For the immunoblotting 
technique, the volume of buffer used to solubilize the 
delipidated plasma sample was 100 /iL for each mmol/L 
triglyceride present in plasma sample. The solubilizing buffer 
was the same as that employed for solubilizing the delipidated 
VLDL.
Neuraminidase treatment of VLDL. The isolated VLDL 
fraction {75 /iL) was mixed with an equal amount of neuramini­
dase solution (5 U/mL, in 0.1 mol/L acetate buffer, pH 4.5), 
and incubated for 2 h at 37 *C. Delipidation and solubiliza­
tion was followed as described for VLDL above (II.4.1, p. 40).
Neuraminidase treatment of plasma sample. Plasma samples 
(10 (iL) were mixed with an equal volume of neuraminidase 
solution, and incubated for 2 h at 37 *C, followed by
delipidation and solubilization as described above (II.4.1, p.
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Cysteamine treatment. The VLDL fraction (75 /iL) was 
incubated with an equal volume of cysteamine hydrochloride 
solution (0.1 mol/L Tris-HCl buffer, pH 10.3, containing 2.9 
mmol/L cyteamine hydrochloride) at room temperature for 4 h, 
followed by delipidation and resolubilization as above, except 
that the dithiothreitol was omitted from the solubilizing 
solution.
Sample treatment for screening of apo AI and All. Serum 
(5 /iL) was incubated with 5 /iL of 0.05 M Tris-HCl buffer, pH
8.2, containing 25 mM of DTT, 6 M urea, and 0.5% Nonidet P-40 
for 30 min. Two nL of diluted plasma sample were applied to 
the gel for lEF.
II.4.2. choJLeaterol and triglyceride analysis 
Total cholesterol (TC), total triglyceride (TG), VLDL- 
cholesterol (VLDL-C), and VLDL-triglyceride (VLDL-TG) were 
quantified by enzymatic methods, using a Kodak Ektachem 700 
analyzer. These methods utilized the following principles: 
Total triglyceride
Lipoproteins Surfactant ^ TG + Proteins
TG + 3 H,0 Lipase ^ Glycerol + 3 Fatty acid
Glycerol + ATP Glycerol kinase ^  Glycerol-3-phosphate + ADP
Glycerol-3-phosphate + o, Glvcerol phosphate oxidase ^
Dihydroxyacetone phosphate + H,0, 
HaOj + Leuco dye Peroxidase ^ Dye + 2HjO
The concentration of triglycerides present in the sample
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was determined by measuring the density of the dye by
reflected light at 540 nm.
Total cholesterol
Lipoprotein Surfactant ^ Lipid + Proteins
Cholesterol esters Cholesterol esterase ^  C + Fatty acids
C + Oj Cholesterol oxidase ^ Choles-4-ene-3-one + HaO^
2 HaOa + Leuco dye Peroxidase ^ Dye + HjO
The density of the dye was measured by reflected light at 670
nm which correlated to total cholesterol in the sample.
Kodatrol assayed controls, level I and II, were routinely 
included in each batch of patient specimens. The methods were 
standarized using Kodak Ektachem calibrators which are
traceable to the Center for Disease Control, Atlanta, GA
(reference methods for cholesterol and triglyceride),
II.4.3. Lipoprotein electrophoresis
Lipoprotein electrophoresis was carried out on agarose 
gel according to the kit manufacturer's instructions (Beckman 
Instruments, Inc.). VLDL fraction or plasma (3-5 /iL) was 
applied across each template slot (eight samples could be 
applied per gel). The gel was placed in a Paragon
electrophoresis cell and covered. The Paragon electrophoresis 
cell was inserted in the power supply and lipoprotein 
electrophoresis was run for 30 min at 100 V. Upon completion 
of electrophoresis, the gel was placed in fixative for 5 min, 
after which it was placed in a Paragon dryer until completely 
dried. The dried gel was processed in the following manner: 5
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min in the lipoprotein working stain; 3 dips in the first 
destaining solution; 3 dips in the second destaining solution;
5 min in the third destaining solution; and finally, rinsed 
with distilled deionized water and dried.
11.4.4. Polyacrylamide gel preparation
Two flat gels (125 x 65 x 0.4 mm) were cast using the 
following method. A mixture of 4.2 g urea, 2 mL of monomer 
concentrate, 2 mL of 25% w/v glycerol, 0.5 mL of ampholyte (pH 
4-6, 5-7 in a ratio of 4/1) was prepared. Enough distilled 
deionized water was added to the mixture to make a final 
volume of 10 mL. The final concentrations of the above 
ingredients were: urea, 7 moles/L; monomer concentrate, 5% T 
and 3% C (T denotes the total percentage concentration of 
monomer and bis-acrylamide, C denotes the total percentage of 
the crosslinking agent in total gel composition); and 
glycerol, 5% w/v. The solution was mixed and degassed for 5 
min under vacuum. Ammonium persulfate (20 pL of 10% w/v), 50 
fiL of 0.1% w/v riboflavin-5'-phosphate and 3 /iL of TEMED were 
added. The mixture was poured onto two glass plates which were 
placed on a casting tray, followed by irradiation with a 
fluorescent lamp for 1 h as described in the Model ill Mini 
lEF Cell instruction manual (Bio-Rad).
11.4.5. Isoelectric focusing (lEF)
lEF was performed according to the cell manufacturer's 
instructions (Bio-Rad). Without prefocusing the gel, the 
sample applicator was placed onto the gel surface and 2 /iL of
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delipidated VLDL were applied (up to 10 samples were applied 
on the same gel). The sample was allowed to diffuse for 5 min 
into the gel- Electrofocusing was run for a total of 90 min as 
follows: 15 min at 100 V; 15 min at 200 V; and 60 min at 450 
V. The gel was then fixed immediately in a fixative solution 
(4% w/v sulfosalicylic acid, 12.5% w/v trichloroacetic acid, 
and 30% v/v methanol) for 30 min and stained with either 
silver stain or CBB R-250 or CBB G-250.
II.4.6. Staining
Cooaassie brilliant blue R-250. The gel was stained with 
CBB R-250 for 2 h, followed by two or three changes of the 
first destaining solution for 15 min each, then two changes 
with the second destaining solution for 15 min each. The gel 
was allowed to dry in a fume hood.
Coomassie blue G-250. The gel was placed for 1 h in this 
stain, after which it was immediately placed in 7% v/v acetic 
acid for color intensification and preservation. This 
technique was nearly as sensitive as CBB R-250 staining, but 
required no destaining and did stain ampholytes.
Silver stain. This technique was 10 to 50 times more 
sensitive than CBB R-250. After fixation as previously 
described (see above II.4.5), the gel was placed in two 
changes of 300 mL each of the second fixative solution (10% 
ethanol v/v, 5% v/v acetic acid) for 15 min each, followed by 
100 mL of oxidizer solution for 3 min. The gel was washed with 
3 to 4 changes of distilled deionized water for 10 min each.
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followed by silver reagent for 15 min. The gel was washed for 
2 min in distilled deionized water, then placed in the 
developer solution for two changes- first change, 30 sec, or 
until a brown "smoky" precipitate appeared, followed by 
second change of developer solution for up to 5 min. Finally, 
the reaction was stopped by placing the gel in 5% acetic acid.
The destained gel was dried in a dust-free area with good 
ventilation (fume hood) over night at room temperature.
11.4.7. Scanning densitometry
Isoelectric focused gels stained with CBB R-250 were 
scanned at 570 nm (II.2, P. 30), and the background of the gel 
was used as a blank. The densitometric area for the apo CII 
isoform was corrected by a factor of 1.25 as recommended by 
Catapano et al. (186).
11.4.8. Immunof ixation
Immunofixation of. apo E. After completion of lEF, 
phenotyping of apo E was carried out by fixing the gel 
immediately with anti apo E solution (goat anti-human 
apolipoprotein E diluted 10 fold with 50 mmol/L Tris-HCl 
saline buffer pH 7.4), and incubated at 37 'C for 1 h. The gel 
was washed 4 times, 15 min each, with 0.1 mol/L Tris-HCl 
saline buffer pH 7.4, and stained with CBB R-250 or silver 
stain.
Immunofixation of apo AI. This method was carried out 
exactly as described for immunofixation of apo E, except that 
goat anti-human apolipoprotein AI was diluted 5 to 6 fold.
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II.4.9, immunoblotting
After isoelectric focusing of delipidated and solubilized 
plasma samples, the protein bands were transferred to 
polyvinylidene difluoride membrane (PVDF) by uni-directional 
diffusion using the apparatus illustrated in Fig 1. This 
procedure (modified from Smith (192)) was carried out as 
follows:
The PVDF membrane was allowed to float in 100% methanol for 15 
min, followed by 15 min equilibration with the transfer buffer 
(7mM Tris-HCl buffer, containing, 250 mM glycine and 20% 
methanol, pH 8.0). The gel was overlaid with the prewetted 
PVDF membrane, and covered by a prewetted wick of 3 mm filter 
paper. A stack of dry 3 mm filter paper and a weight of 300 g 
was placed on top (Fig 1). The reservoirs were covered with 
aluminium foil to minimize evaporation, and the apparatus left 
at room temperature overnight. The apparatus was then 
deassembled, and the membrane was rinsed with TBST. To 
saturate the non-specific binding sites, the membrane was 
incubated for 1 h with 5% low-fat dry milk made up in TBST. 
The membrane was rinsed and placed in TBST containing primary 
antibody (anti-apo AI or anti-apo All or anti-apo E) diluted 
1:1000 and incubated for l h. The membrane was washed three 
times in TBST for 15 min each to remove unbound antibody, 
followed by 1-h incubation in TBST containing 1:1000 anti-IgG 
alkaline phosphatase conjugate, followed by 3 washes in TBST 
as above. The color reaction was started by adding the
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FIGURE 1 
WESTERN-BLOT APPARATUS
Legend
Apparatus for the transfer of proteins from ultrathin 
polyacrylamide gel to PVDF membrane by uni-directional 
diffusion (192).
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substrate solution (66 /iL NBT,and 3 3 pL BCIP) to the membrane, 
and incubated with stirring until an adequate color was 
observed. The reaction was stopped by placing the membrane in 
distilled deionized water.
II.4.10. Determination of isoelectric points of 
apoiipoprbtsins E, c, and h 
standard lEF markers of low pi were used to determined 
the pi of apolipoprotein isoforms. These standards were 
trypsin inhibitor (pi 4.6), B-lactoglobulin A (pi 5.1), and 
carbonic anhydrase I from human erythrocytes (pi 6.6).
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CHAPTER TTT 
RESUT,TS AND DISCUSSION
T T T . l  C o m p a r i s o n  o f  V I , D L  I s o l a t e d  b y  t h e  A i r f u g e  a n d
P r é p a r â t  i y e  U 1 t r a c e n t r i  f u g e
A mioromethod for serum lipoprotein fractionation from 
150 fil- of serum by means of an air-driven, table-top 
ultracentrifuge (Beckman Airfuge®) was first described by 
Bronzert and Brewer (191), and later modified by Strobl and 
Widhalm (189). The separation of VLDL from the infranate (LDL 
+ HDL) was performed by either vacuum aspiration (193) or tube 
slicing (189). The aim of previous work was the direct 
determination of cholesterol in VLDL, and none of the 
investigators have used the VLDL isolated by the Airfuge for 
phenotyping of apo E or apo C.
In this research, the Airfuge method used to isolate VLDL 
was a modification of the procedure of Strobl and Widhalm 
(189). Therefore, the purity of VLDL and the concentration of 
its constituents (cholesterol and triglyceride) had to be 
studied and compared to the conventional method (preparative 
ultracentrifuge) before conducting further experiments for 
phenotyping of apo E and quantifying the isoforms of apo C.
TTT.1.1 Lipoprotein electrophoresis
The quality of VLDL separated by the Airfuge was compared 
to that isolated by preparative ultracentrifugation, and
51
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evaluated by lipoprotein electrophoresis in agarose gel (Fig.
21 . The VT.DT, isolated by the Airfuge (lane 3) showed no 
difference from that isolated by the preparative 
ultracentrifuge (lane 2). When compared to a plasma sample 
(lane 1), the VLDT, isolated by both methods showed no 
contamination with either T.DT, or HOT,. Similar results were 
obtained when VT.DT. was isolated from plasma samples with 
elevated cholesterol (C) and triglycerides (TG) concentrations 
as shown in lanes 4 and 5 of Fig. 2 wnere the VT.DT, was 
isolated by the preparative ultracentrifuge and Airfuge, 
respectively, and in lanes 6 and 7, where VT.DT. was isolated by 
preparative ultracentrifuge and Airfuge, respectively.
III. 1.2. Comparison of VT.DT-.-C and (T.DT.+HDLl-C isolated 
by the Airfuge and preparative ultracentrifuge
VLDL fractions were isolated from 21 plasma samples by 
means of an Airfuge and a preparative ultracentrifuge, and 
cholesterol was determined on VLDL and pooled (LDL + hdt.) 
fractions obtained by both methods. Table IV gives the mean of 
cholesterol concentrations in whole plasma and in the VT.DL and 
pooled (LDL+HDL) fractions isolated by the Airfuge. These 
results were compared to those obtained In the preparative 
ultracentrifuge. No significant differences in the mean values 
were found (p > 0.05).
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FIGURE 2
T.ÏPOPROTETN ET.ECTROPHORESTS ON VT.DT. TSOTATED BY ATRFÜGE
AND PR EPAR ATIVE m ,TR AC EN TR IFU G R
T.egend
Agarose gel electrophoresis of 1. ipopoproteins. Lane 1, plasma 
sample, C 3.75 mmol /T., and TG 1.48 mmol/L; lane 2 and lane 3, 
VT.DT. isolated by preparative ultracentrifuge and Airfuge, 
respectively, from plasma sample in lane 1; lanes 4 and 5, 
VT.DT. isolated by preparative ultracentrifuge and Airfuge, 
respectively, from plasma sample, C 5.74 mmol/L, and TG 9.90 
mmol/L; lanes 6 and 7, VLDL isolated by preparative 
ultracentrifuge and Airfuge, respectively, from plasma sample, 
C 9.75 mmul/L, and TG 19.99 mmol/L.
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TA B l.R  TV
COMPARISON OP PTASMA VT.DT-C AMD (LDT. +  H D T .)-C  CONCENTRATIONS
DETERM INED ON V I.D L  IS O TA TE D  BY THE A IR FU G E AND
PR EPAR ATIVE UT.TRACENTRIFUGE
Airfuge 
(Mean + SD, 
mmol/L)
Preparative 
ultracentrifuge 
(Mean ± SD, mmol/L)
VLDL-C" 1.10 t 0.46 1.17 + 0.46»
(LDL + H D D - C 4.43 + 1.16 4.29 ± 1.11»
Total-C 5.48 ± 1.22 5.48 ± 1.22
N" 21 21
" VLDL was removed by pipeting in both methods.
Not significant (p > 0.05).
' Total cholesterol in plasma (mmol/L).
■’ Number of samples.
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T T T . 1 . 2 .  I  A n a î y f r i c a î  r e c o v e r y .  T a b l e s  V  and V T  show the 
r e s u l t s  of a n a l y t i c a l  recovery on 1 i poprotein-cholesterol 
fractions prepared b y  the Airfuge and preparative
ultracentrifuge, respectively. A mean recovery ( N  -  21 1 of 101  
+ 1 % (mean t SD) of lipoprotein cholesterol as compared to 
total cholesterol assayed in whole plasma was achieved by the 
Airfuge® method (Table V), versus 1 0 0  + 4 % (mean + SD) by 
preparative ultracentrifugation (Table VT).
ITI.l.2.2 Correlation studies. Figures 3 and 4 show the 
correlations between the lipoprotein cholesterol values 
determined by means of the Airfuge and the reference method 
(preparative ultracentrifuge). Close correlations over a wide 
range of concentrations were observed. A correlation 
coefficient of r = 0.96 (N = 21), and a regression equation Y 
= 0-95X - 0.0016 were obtained for VLDL-C (Fig. 3). The
correlation studies for (LDL + HDL)-C are shown in Fig.4, (r 
= 0.988, N = 21), regression equation Y = 1.02X + 0.038.
III.1.2.3. Precision studies. One patient sample of 
plasma cholesterol and triglyceride of 6.16 and 1.31 mmol/I,, 
respectively, was used to determine the within-run and 
between-run variations (Table VIT) . The within-run coefficient 
of variation (CV's) achieved by the Airfuge for VLDL-C and 
(HDL + LDL)-C were 2.4% and 5.3%, respectively. Between-run 
CV's for VLDL-C and (LDL + HDL)-C were 1.5% and 2.5%, 
respectively.
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TABT.R V
ANAT.YTTCÀT. RECOVERY FOR ETPOPROTETN-CHOLESTEROL 
TSOTJkTED BY ÀIRFOGE
Plasma total-C 
(mmol/L)
VLDL-C + (LDL + HDL)-C 
(mmol/L)
Recovery*
(%)
3.58 3.60 101
4.66 4.76 102
6.63 6.55 99
3 . 51 3.86 110
6.42 6.50 101
5.80 5.91 102
6.07 6.37 105
6.90 6.84 99
5.54 5.66 102
6.78 6.83 101
3.98 3.96 99
5.79 5.85 101
5.66 5.87 104
5.74 5.77 101
3.88 3.80 98
5.36 5.04 94
8.02 8.00 100
6.63 6.94 105
5.42 5.41 100
4.29 4.34 101
4.44 4. 34 98
" Analytical recovery for the Airfuge was 101 ± 3 % (Mean t 
SO), N = 21
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TABLE VT
ANALYTTCAI. RECOVERY FOR T.TPOPROTETN-CHOT.ESTEROÏ. 
ISOLATED BY PREPARATIVE ULTRACENTRIFUGE
Plasma total-C 
(mmol/L)
VLDL-C + (LDL + HDL)-C 
(mmol/L)
Recovery"
(%)
3 . 58 3.62 101
4 .66 5.07 109
6.63 6.51 98
3.51 3.81 108
6.42 6.75 105
5.80 5.58 96
6.07 6.22 1 02
6.90 7.00 101
5.54 5.52 100
6.78 6.57 97
3.98 3 .88 97
5.79 5.34 92
5.66 5.80 1 02
5.74 5.75 100
3 . 88 3.73 96
5.36 4.92 92
8.02 7.91 99
6.63 6.77 102
5.42 5.38 99
4.29 4 . 24 99
4.44 4.33 98
Analytical recovery for the preparative ultracentrifuge was 
100 ± 4 % (Mean + SD), N = 21.
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FIGURE 3
COMPARISON OF VLDL-C ISOTATED BY THE AIRFUGE AND
PREPARATIVE UT-TRACENTRTFUGE
Legend
The equation of the regression line is Y = 0.95X - 0.0016, (r 
= 0.96, N = 21).
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FIGURE 4
COMPARISON OF (T.DT, + HUTJ-C ISOTATED BY THE AIRFUGE AND
PREPARATIVE in.TRACENTRIPUGE
Legend
The equation of the regression line is Y = 1.02X + 0.038, 
(r = 0.988, N = 21).
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TABI.E VTT
PRECISION STUDIES FOR 
DETERMINED
VT.DI.-C AND (LDL + HDL)-C 
BY AN AIRFUGE
WitMn-run Between-run
VLDL-C (LDL + HDL)-C VLDL-C (LDL + HDL)
(mmol/L) (mmol/L) (mmol/L) (mmol/L)
1 0.72 5.80 0.70 5.66
;> 0 .68 5.87 0.72 5.86
3 0. 72 5.87
4 0.68 5.54
5 0.71 5.10
6 0.69 5.78
N 6 6 2 2
Mean 0.70 5.66 0.71 5.76
SD 0 .017 0.30 0.01 0.14
CV{%) 2.40 5.30 1.50 2.48
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TTT.1.3. Comparison of VT.DT.-TG and (T.DT, + HDT.)-TG 
isolated by the Airfuge and preparative 
ultracentri fuge 
levels of TG were determined on the 21 VI,DT, fractions 
isolated by means of the Airfuge and preparative ultra­
centrifuge. Table VTTT shows the mean of TG concentration in 
plasma, in VLDL, and in pooled (LDL + HDL) fractions isolated 
by the Airfuge. These results were compared to those obtained 
by preparative ultracentrifugation. No significant differences 
in the mean values were found (p > 0.05).
III.1.3.1 Analytical recovery. Tables IX and X show the 
results for analytical recoveries of triglycerides on VLDL-TG 
+ (LDL + HDL)-TG fractions isolated by both methods from 21 
patients samples. A mean recovery of 95 ± 5 % of lipoproteins 
triglycerides as compared to total plasma triglycerides was 
achieved by the Airfuge method (Table IX), versus 94 + 6 % 
(mean ± SD) by preparative ultracentrifugation (Table X).
III.1.3.2. Correlation studies. Figures 5 and 6 show the 
correlations between the lipoprotein triglyceride values 
determined by the Airfuge and preparative ultracentrifuge. A 
close correlation over a wide range of concentrations was 
observed. A correlation coefficient of r = 0.997, (N = 21), 
and a regression equation of Y = X + 0.008 were obtained for 
VLDL-TG (Fig. 5). For (LDL + HDL)-TG a correlation of r = 
0.998 (N = 21) and a regression equation Y = 1.05X - 0.04 was 
obtained (Fig. 6).
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TABLE VTTT
COKPARi: ON OF PTASMA VT,DT.-TG and (T.DT. + HDT.)-TG CONCENTRATIONS
DETERMINED ON VT.DT. ISOTATED BY THE AIRFUGE AND
PREPARATIVE ULTRACENTRIFUGE
Ai rfuge* 
(mean t SD, 
mmol/L)
Preparative 
ultracentrifuge 
(mean ± SD, mmol/L)
Vl.DI.-TG" 1.86 ± 1.53 1.84 ± 1 .53b
(LDL + HDD-TG 1.96 ± 1.02 1.91 + 0.98b
Total-TG'^ 3.97 + 2.55 3.97 ± 2.55
N" 21 21
" VI.DL was removed by pipeting in both methods. 
" Not significant (p > 0.05).
Total cholesterol in plasma (mmol/L).
' Number of samples.
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TABT.E TX
ANALYTICAL RECOVERY FOR TRTGT.YCERinES IN T.IPOPROTEIN 
FRACTIONS ISOTATED RY THE AIRFUGE
Plasma total-TG 
(mmo1/L)
VT.DT.-TG + (T.DT, + HDT,)-TG 
( mmol /T.)
Recovery'
(%)
1 .83 1 .74 95
2 . 58 2.42 94
2 .03 1 .95 96
1.99 1 .98 99
2.42 2 . 35 97
3.37 3.09 92
1.85 1 . 83 99
3 .68 3 .69 100
8 .80 8 .60 98
4.07 3.95 97
3 .10 2.73 88
1.98 1 .81 91
4.25 4.12 97
9.90 9 . 20 93
9.20 9.18 1 00
2.62 2.52 96
6 . 44 6-42 100
5.76 5.70 99
3.06 2.99 98
2.31 1 - 82 79
2 . 22 2.05 92
" Analytical recovery by the Airfuge was 95 t 5 %, (Mean t 
SD), N = 21.
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TABT.E X
ANAT.YTTCAT, RECOVTtRY FOR TRIGLYCERIDES IN T.IPOPROTEIN FRACTIONS 
ISOTATED BY PREPARATIVE TJT.TRACIÎNTRIFTJGE
Plasma total-TG 
( mmo 1 /T. )
VLDL-TG + (LDL + HDL)-TG 
(mmol/L)
Recovery"
(%)
1 .83 1 .58 86
2.58 2.18 84
2.03 1 .95 96
1 .99 2 . 05 103
2.42 2.18 90
3.37 3.01 89
1 .85 1.85 100
3 .68 3.56 97
8.80 8.75 99
4.07 3.93 97
3.10 2.69 87
1.98 1.80 91
4.25 4.05 95
9.90 8.77 89
9. 20 9.01 98
2.62 2.60 99
6.44 6.39 99
5.76 5.57 98
3 .06 2.90 95
2.31 1.84 80
2.22 2.09 94
Analytical recovery by the Airfuge was 94 ± 6%, (Mean ± SD), 
N = 21
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FIGURE 5
COMPARISON OF VT.DT .-TG ISOTATED BY THE AIRFUGE
AND PREPARATIVE TU.TRACENTRTFUGE
Legend
The equation of the regression line i s  Y =  X  + o.OOfl, ( r  
0.997, N = 21) .
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FIGURE 6
COMPARISON OF ( T.DT. + HDT.)-TG ISOTATED BY THE AIRFUGE
AND PREPARATIVE UT.TRACENTRIFUGE
Legend
The equation of the regression line is V = 1.05X - 0.04, (r 
0.998, N = 21).
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TTT.1.3.3. Precision stud i e s . A plasma sample of 
triglyceride concentration 1.11 mmol/T., was used to determine 
the within-run and between-run SD's (Table XT), The within-run 
CV's achieved by the Airfuge for VT.DT,-TC and (T.DT. + HDT.l-TG 
were 1.2% and 1.6%, respectively. Between-run CV's for VT.DT,-TC 
and (LDL + HDL)-TG were 0.85 and 0.1%, respectively.
TIT. 1.4. Comparison..of_calculatecî VLDL-C versus VT.DT.-C 
isolated.by the.Airfuge.
The indirect estimation of cholesterol in T.DL by use of 
the Friedewald formula (LDL-C = total-C - HDL-C - 0.45 x serum 
TG, where all concentrations are in mmol/L) (194), allows T.DT.- 
C to be calculated without individual separation of T.DT, and 
VLDL. The accuracy of this formula depends on several factors: 
the ratio of the amount of TG to C in VLDL (apparently 
relatively constant and about 5:1 in normal subjects) (195); 
a TG concentration of < 4.5 mmol/L in serum; the lack of 
chylomicrons and VLDL remnants; the precision of the method 
used for measuring C and TG; and the effectiveness of 
procedures for HDL separation. Furthermore, the relation 
between the concentration of serum TG and VLDL-C is dependent 
on age, sex, ethnic, and sociodemographic variations of the 
subjects studied (196). Unfortunately, the ratio of TG to C in 
VLDL is not always constant, and a hypertriglyceridemia >4.5 
mmol/L is relatively frequent, and so the Friedewald formula 
is not applicable to a large proportion of samples.
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TABLE XT
PRECISION STUDIES FOR VT.DT. 
DETERMINED BY
-TG AND (T.DT. 
AN AIRFUGE
+ HDD-TG
Withinrrun Between-run
VLDL-TG (LDL + HDL)-TG VLDL-TG (LDL + HDL)
(mmol /I.) (mmol /I.) (mmol/L) (mmol/L)
1 0.42 0.94 0.42 0.95
2 0.41 0.93 0.41 0.95
3 0.41 0.95
4 0.41 0.94
5 0.42 0.97
6 0.42 0.96
N 6 6 2 2
Mean 0.42 0.95 0.41 0.95
SD 0.005 0.015 0.004 0.003
CV (%) 1.20 1.60 0.85 0.30
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Samples in which the plasma total TG were determined, 
were separated into two groups, one group with plasma total TG 
<4.5 (N = 121, and the other group with plasma total TG 4.5 
mmol/L (N = 8). Cholesterol in VT.DT, fractions isolated by the 
Airfuge for both groups was determined and compared to the 
calculated value (VT.DT.-C = 0.4 5 x serum total TG) (194-197). 
The correlation study for the first group (TG < 4.5 mmol /T.) is 
shown in Fig. 7. A correlation coefficient of r = 0.93, and a 
regression equation of Y = 0.89x + 0.18 was obtained between 
calculated VLDL-C and VLDL-C determined by an Airfuge. The 
other group (TG > 4.5 mmol/L), showed a correlation
coefficient of r = 0.83, and a regression equation of Y = 
7.09X -10.06 (Fig. 8). The correlation coefficient in Fig. 8 
was even worse when the last point on the graph (plasma total 
C 3 2 mmol/L and TG 131 mmol/L) was dropped (r = 0.40). 
Therefore, this present study agreed with previous 
investigators (194-197), that the estimation of VLDL-C and its 
extrapolation to estimate LDL-C is unsuitable for those 
samples with plasma total TG > 4.5 mmol/L. The current
modified method for isolation of VLDL by the Airfuge, showed 
to be a suitable alternative procedure for determination of 
VLDL-C and further for the estimation of LDL-C.
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FIGURE 7
COMPARISON OF CAT.CUTATED VT.DT.-C AND VT.DT.-C OBTAINED BY THE 
AIRFUGE FOR SAMPI.ES WITH PTASMA TOTAL TG < 4.5 KHOT./I.
T.egend
Calculated VLDL-C from plasma total TG (TG < 4.5 mmol/L) 
versus cholesterol determined on VLDL isolated by the Airfuge. 
The equation of the regression line is Y = 0.89x + 0.18,
(r = 0.93, N = 12).
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FTGtmF 8
COMPARISON OF CAT.CinATKO VT.DT-C AND VT.DT.-C OBTAINED BY THE 
AIRFUGE FOR SAMPT.ES WITH PTASMA TOT AT. TG > 4.5 MMOL/L
T.^end
Calculated VT.DT.-C from plasma total TG (TG > 4.5 mmol /T.) 
versus cholesterol determined on VLDL isolated by the Airfuge. 
The equation of the regression line is Y = 7.09x - 10.06,
(r = 0.83, N - 8).
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TTT.7. Phenotyping of Apolipoprotein P 
TTT.7.1. Identification of apo F isoforms 
The isoelectric focusing method reported in this study 
allowed VT.DT, apo F to be resolved into three major peptide 
bands which were identified by two methods,i.e., cysteamine 
treatment, and immunofixation.
TTT.2.1.1. Cysteamine treatment. Cysteamine specifically 
reacts with the cysteine residues of apo F to introduce an 
amino group, thereby increasing the net charge of the protein 
by one positive charge for each cysteine residue (198). The 
result of cysteamine treatment is that apo E, (two cysteine 
residues) and apo E., (one cysteine residue) both focus in the 
same position as E, (two arginine residues) (Fig. 9). 
Cysteamine treatment, therefore, confirms that the observed 
charge differences are due to Arg-Cys substitutions which 
allowed positive identification of the apo E isoforms.
III.2.1.2. Immunofixation. The second method used for 
identifying apo E isoforms was immunofixation. Figure 10 shows 
a typical lEF pattern for apo E isoforms. This figure shows 
good resolution of the apo E isoforms with pi's in the range 
of 5.58 to 5.99. In lane 2 of this figure, the more anodic 
bands seen are those of apo C. These bands are not seen in 
lane 3, where anti-apo E antibody was used to fix the apolipo- 
proteins. Immunofixation may be useful where the apo E 
concentration in the VLDL fraction is low, or where there is 
contamination of VLDL with proapolipoprotein A1 (199), or
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
RO
FIGURE 9
ISOET.FCTRIC FOCUSING PATTERN OF VT.DT. APO E WITH AND WITHOUT
CYSTEAMINE TREATMENT 
T.egend
Isoelectric focusing pattern of del ipidated VLDL Apo E. 
VT.DT. was isolated using the Airfuge as described in (IT. 4.1, 
P. 38) Lane 1, mixture of three TEF marker proteins (starting 
from the cathode, these markers are: carbonic anhydrase I from 
human erythrocytes, pi 6.6; B-lactoglobulin, pi 5,1; and 
trypsin inhibitor, pi 4.6); lane 2. delipidated VLDL; lane 3, 
cysteamine treated and delipidated VLDL. The gel was stained 
with CBB R-250.
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FTGirRR 10
TDRNTTFTCATTON OF APO E BY TMMIJNOFTXATTON
legend
Identification of Apo F by immunofixation. Lane 1, IFF 
of a mixture of three marker proteins (starting from the 
cathode, these markers are: carbonic anhydrase I from human 
erythrocytes, pT 6.6,* B-lactoglobul in, pT 5.1; and trypsin 
inhibitor, PT 4.6); lane 2, delipidated VLDL (both lanes 1 and 
2 were fixed with trichloroacetic acid and sulfosalicylic 
acid, and stained with silver stain); lane 3, delipidated VLDL 
sample of lane 2, immunofixed with anti apo E antibody and 
stained with CBB R-250.
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serum amyloid A (200). Tn these cases, additional bands may be 
seen in the apo K region which may complicate the 
interpretation of apo R phenotyping. The minor bands in lanes 
2 and 3 are the sialylated forms of apo R (R\, pT of 5.67; and 
R/, pT of 5.58) which focused closer to the anode than the 
parent protein. The sialic acid residues on these minor bands 
can be eliminated by sialidase treatment. The immunofixation 
of delipidated VLDL obtained from sialidase-treated samples 
allow unambiguous determination of apo E phenotypes since the 
minor bands are no longer visible.
TIT.2.2. Comparison of VLDL apo E isolated by the Airfuqe and 
preparative ultracentrifuge 
The isoelectric focusing pattern of VLDL isolated by the 
rapid Airfuge method was similar to that of VLDL isolated by 
preparative ultracentrifugation (Fig. 11). The apparent 
isoelectric points (pl.pp) for apo E isoforms agreed with those 
reported by Warnick et ai.(176) and Eto et al. (177) (Table 
XII). The three bands obtained can be assigned as E^ , E,, or 
E, on the basis of their position relative to the pi markers 
and the preponderance of the E, allele as shown by 
densitometry.
ITT.2.3. Determination of pi in a gel containing urea
When a pH gradient is measured in urea, the apparent pH 
cannot be compared directly with that obtained in normal 
aqueous solution (201). Not only is there a conformational 
change in the structure of the protein which potentially gives
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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FIGURE 1 1
COMPARISON OP ISOET.ECTRIC FOCUSING PATTERNS OF VT.DT. APO E 
ISOTATED BY THE AIRFUGE AND PREPARATIVE UT.TRACENTPIFUGE
legend
Comparison of VT.DT. isoelectric focusing patterns. T.ane 
1, mixture of three IFF marker proteins (starting from the 
cathode, these markers are : carbonic anhydrase I from human 
erythrocytes, pi 6.6; B-lactoglobulin, pi 5.1; and trypsin 
inhibitor, pi 4.6); lane 2, VT.DT. (75 pT.) isolated by the 
Airfuge and delipidated; lane 3, VT^ DT. (200 pT.) isolated by 
preparative ultracentrifugation and delipidated. The gel was 
stained with CBB R-250.
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TA B LE  XTT
APPARENT TSOKT.ECTRTC POINTS OF APO E ISOFORMS
Obta ined' 
(pl)
Warnick et a?. 
(176)
Fto et a ?. 
(177)
Apo E, 6.02 + 0.04 6.1 5.98
Apo E, 5.88 + 0.03 6.0 5.81
Apo E.. 5.72 t 0.03 5.9 5.68
Results of 5 replicate determinations (Mean + SD)
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rise to a change in surface charge, and hence pi, but also 
errors can be introduced by the primary medium effect, and by 
the effect of the pH measuring cell (202-204). The primary 
medium effect is the change in pH caused by the effect of the 
urea on both the carrier ampholyte and water, altering the 
ionization constant of individual groups and therefore affects 
the PI of the protein. The effect of the pH measuring cell is 
related to the effect of the urea on the glass electrode. Thus 
the pH of the protein in concentrated urea solution cannot be 
easily correlated with that obtained in an aqueous 
environment, and results in urea have no physical meaning 
although they are of relative use (201). Another problem may 
arise from using urea, which can contribute to the shift of 
the protein markers, is that urea and ammonium cyanate form an 
equilibrium pair. Thus, there is always the risk of carbamy­
lation when using urea, not so much for the ampholytes (very 
few primary amino groups) as for the proteins (205). The risk 
is fairly low with fresh urea solutions at room temperature, 
but increases as the temperature rises.
Standard lEF markers of low pi were used to determine 
the isoelectric points of all apoproteins isoforms used in 
this study. These standards were: trypsin inhibitor (pi 4.6); 
5-lactoglobulin (pi 5.1); carbonic anhydrase II from bovine 
erythrocytes (pi 5.4); carbonic anhydrase II from bovine 
erythrocytes (pi 5.85); and carbonic anhydrase I from human 
erythrocytes (pi 6.57). The PI of these markers were those
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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quoted by the manufacturer, Sigma Chemical Company, (the pT's 
were measured in aqueous solution media without ureal. For the 
present study, urea must be included in the polyacrylamide gel 
isoelectric focusing (PAGTFl for a good separation of the 
apolipoproteins investigated. The amount of shift in the pT of 
the above markers caused by urea was noticed when these 
markers were run on PAGTF in the absence and presence of urea 
in the gel. Tn the absence of urea (Fig. 12), a poor 
separation of the apolipoproteins in the delipidated VI,DT. 
samples is shown in lanes 9 and 1G of Fig. 12. A calibration 
curve for the markers in which the distance of each marker 
(band) from the cathode versus the pT of each marker was 
plotted (Fig. 13). The equation of the regression line is Y = 
-1.47X + 9.94, with a correlation coefficient of r = 0.98. 
However, when these markers were run on PAGTF with 7 mol/T, 
urea in the gel, a shift in the pi of two markers (carbonic 
anhydrase II from bovine erythrocytes, pi 5.4 and 5.85) 
towards the cathode was observed as shown in Fig. 14 (lane 1), 
with a good separation of the apolipoprotein bands (lanes 6- 
8). A calibration curve for the markers in which the distance 
of each band from the cathode versus the pi of each marker was 
plotted (Fig. 15). The regression line equation for this curve 
was Y = -1.79X + 11.86 with a correlation coefficient of r = 
0 .86.
The amount of the pi shifts of the markers (pl.,,^  - pi) 
between the media containing urea (pT.pp) and media without
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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FIGURE 12
SEPARATION OF TUE PROTEIN MARKERS AND APOPROTEINS ON A
PAGIF WITHOUT UREA
lÆgend
The polyacrylamide gel was prepared as reported in (II.4.4, p. 
44) (5% T, 3% C, 5% glycerol, and a mixture of ampholytes of 
pT range 4-6, 5-7, in a ratio of 4/1).
T.ane 1 , mixture of 5 IFF marker proteins (starting from the 
cathode, these markers are: carbonic anhydrase I from human 
erythrocytes, pi 6.6; carbonic anhydrase II from bovine
erythrocytes, pi 5.85; carbonic anhydrase IT from bovine
erythrocytes, pi 5.4; S-lact.oglobulin, pi 5.1; and trypsin
inhibitor from soya bean, pi 4.6); lane 2, trypsin inhibitor, 
pi 4.6; lane 3, B-lactoglobul in, pi 5.1; lane 4, carbonic
anhydrase I from human erythrocytes, pi 6.6; lane 5, carbonic 
anhydrase II from bovine erythrocytes, pi 5.85; lanes 6-8, are 
VT.DT. samples without delipidation; lanes 9 and 10, delipidated 
and solubilized VLDL.
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FIGURE 13
STANDARD CURVE OF pT MARKER PROTEINS ON PAGIF
WITHOUT UREA
Legend
Five marker proteins were run in duplicate on gels made to 
contain 5-\ T, 3% C, 5% glycerol, and ampholyte of pi range 4- 
6, 5-7 in a ratio of 4/1.
The equation of the regression line is v = -1.47X + 9.94 
(r = 0.98).
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PTGIIRF 14
SEPARATION OF MARKER PROTEINS AND APOT.IPOPROTEINS 
ON PAGIF WITH UREA
Legend
The PAGTF gel contained 5% T, 3% C, 5% glycerol, and 
7no1/T. urea as described in (IT. 4.4, p. 44).
T.ane 1, mixture of 5 lEF marker proteins (starting from 
the cathode, these markers are: carbonic anhydrase I from
human erythrocytes, pT 6.6; carbonic anhydrase II from bovine 
erythrocytes, pi 5.85; carbonic anhydrase II from bovine 
erythrocytes, pi 5.4; B-lactoglobulin, pi 5.1; and trypsin 
inhibitor, pi 4.6); lane 2, trypsin inhibitor (pi 4.6); lane 
3, B-lactoglobulin (pi 5.1); lane 4, carbonic anhydrase II 
from bovine erythrocytes (pi 5.85); lane 5, carbonic anhydrase 
I from human erythrocytes (pi 6.6); and lanes 6-8, delipidated 
and solubilized VLDL.
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FIGURE 15
STANDARD CURVE OF pi MARKER PROTEINS ON PAGTF WITH UREA
r.egend
Five marker proteins were run in duplicate on a gel made 
of 5% T, 3% C, 5% glycerol, 7 mol/L urea, and ampholyte of pi 
range 4-6, 5-7 in a ratio of 4/1.
The equation of the regression line is Y = -1.79X + 11.96 
(r = 0.86).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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urea (pT) as observed on PAGTF gel are shown in Table XTTT. 
Unfortunately, attempts to correct for the shift in pT values 
for the marker proteins could not be used in this work, simply 
for reasons of comparing our data with that of previous 
workers (176,177), who did not use any corrections for the 
apparent pT of the apoproteins measured either by pH meter 
(176) or by using proteins markers (177). Therefore, the pT's 
of all the apolipoproteins in this study were obtained from a 
standard curve of three marker proteins (carbonic anhydrase IT 
from human erythrocytes, pi 6.57, B-lactoglobulin, pT 5.1, and 
trypsin inhibitor, pi 4.6) (Fig.16). The equation of the 
regression line was Y = -1.70X + 11,93 (r = 0.998).
III.2.4. Optimization of solubilization conditions 
The composition of the solubilizing buffer was 
investigated. When the detergent Nonidet P-40 (0.5%) was
included in the solubilizing buffer, the intensity of apo E 
bands was slightly increased. Similar results were obtained 
using dodecyl sodium sulfate, whereas Triton X-100 was less 
satisfactory. All the detergents tested produced a smeared 
pattern at the point of application. Therefore, whenever 
detergent was included in the solubilizing solution, the 
sample was applied in the middle of the gel and far removed 
from the focusing region of apo E. In the absence of 
dithiothreitol, apo E bands were sometimes split into dimers 
or shifted slightly toward the cathode from the usual focusing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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TABLE XTTT
VAT.UES OF pT.pp - pT FOR THF MARKER PROTETNS
Marker
proteins-
Distance from 
cathode” (cm)
PT" ( pT - pT)-
1 0.70 6 . 29 6.57 - 0.28
2 0.85 6.18 5.85 + 0.33
3 1 .00 6.08 5.40 + 0. 68
4 3.35 4 . 48 5.10 - 0.62
5 4.00 4,04 4.6 - 0.56
" The marker proteins are; 1, carbonic anhydrase T from human 
erythrocytes; 2, carbonic anhydrase IT from bovine erythrocytes; 
3, carbonic anhydrase IT from bovine erythrocytes; 4, B- 
lactoglobulin; 5, trypsin inhibitor.
 ^Distance from the cathode to the focused band on PAGIF gel with 
7 mol/L urea.
 ^Apparent pi of the markers on a PAGIF with urea.
The pi of the marker proteins as given by the manufacturer 
(Sigma Chemical Company), probably measured in aqueous solution 
(media without urea).
* The amount of pi shift represents the difference in pi's between 
the two media (with and without urea).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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FIGURE 16
CALIBRATION CURVE FOR pi MARKER PROTEINS
T.egend
Calibration curve for the determination of isoelectric 
points of apolipoproteins. A mixture of low pi marker proteins 
(trypsin inhibitor, pi 4.6, B-lactoglobulin, pi 5.1, and 
carbonic anhydrase I from human erythrocytes, pi 6.6) was used 
as a standard.
The equation of the regression line is y = -1.70X + 11.93 
(r = 0.998).
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position. This phenomenon was also reported by Warnick et al. 
(176) . VLDL, stored for 2 weeks, showed no change in the
intensity of apo E bands. Solubilized samples can be stored up 
to 3 days at 4“c with no change in the focusing pattern. 
Storage of dissolved samples for more than 3 days resulted in 
additional bands being produced from apo E. These bands may 
arise from inactivation of the sulfhydryl reducing agent 
(181).
III.2.5. Apo E isoforms 
Figure 17 shows the isoelectric focusing patterns of 
VLDL isolated from patients with various apo E phenotypes 
(panel A). Densitometric scans of samples from patients 
heterozygous for apo Ej are shown in panel B, and the ratios 
of apo E3/E2 or apo E4/E2 were calculated from the area of 
each band (see Table XIV). Table XIV also summarizes the lipid 
profile data and the apo E phenotypes of the six patients 
whose apo E patterns are shown in Fig. 17. The increase in apo 
E« can be seen in lanes l, 4, and 6 of Fig. 17A, and as shown 
in Table XIV, was associated with hypercholesterolemia. The 
grossly hypertriglyceridemia plasma of lane 2 (triglyceride 
131 mmol/L) showed an elevated amount of apo E^ which has 
been previously reported in severe hypertriglyceridemia (206). 
The patient with an apo Ej,, phenotype (lane 5, Pig. 17A) had 
a ratio of VLDL cholesterol to total triglyceride greater than 
0.25 (Table XIV), which corresponded to Fredrickson's 
classification of hyperlipoproteinemia Type III (61).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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SAMPT.KS OF STX APO F PHF.NOTYPES AND DKNSTTOMETRY SCANS
T.egend
Isoelectric focusing patterns of VT.DT. apolipoproteins 
from samples with various apo K phenotypes. (A) Separation of 
six apo E phenotypes. (B) Typical densitometer scans of apo E 
isoproteins from Fig. 17 A (lane 2, phenotype E3/2; lane 5, 
phenotype E4/4; lane 6, phenotype E4/2). The gel was stained 
with CBB R-250 and densitometry was performed at 570 nm 
(TT.4.6, p. 45).
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TA B LE  XTV
T.TPTD PROFILES OF VARIOUS APO E PHENOTYPES
Phenotype C TG VLDL-C 
mmol/I,
VT.DL-C/total TG Ratio” of 
i soforms
(I)" 7 . 25 7 . 38 2 . 87 0.170 E4/E3 =1.16
a (2) 32 131 7.7 0.026 E3/E2 = 0.83
•) (3) 6.12 2.38 0.99 0 .138 R3/E2 = 2.38
E, . (4) 8.31 7. 12 2.92 0 .179 E4/E3 = 2.79
Ej/a (5) 4.49 1.29 0.31 0.264 E3/E2 = 0.11
Ev. (6) 8.53 3.12 - - E4/E2 =0.93
Lane number as in Fig. 17A.
Ratio of isoforms based on densitometric scanning.
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T T T . 2.6.Precision study 
The intrassay and interassay CV's for the ratio of apo 
F1/E2 were 6.8% (n = 10) and 9.75% (n = 4), respectively.
ITT.2.7. Tmmunoblctting 
An immunoblotting technique to phenotype apo E was 
attempted in this study. Because the polyacrylamide gels used 
in this method are only 0.4 mm thick, they ara very fragile 
and have to be supported on a plastic backing sheet. This 
sheet prevents transfer of proteins onto an immobilizing 
membrane such as PVDF, either by classical uni-directional 
transfer with a wick underneath the gel as originally 
described by Southern for DNA (207), or by electrophoretic 
transfer (208,209). Therefore, the immunoblotting technique 
adopted in this study, as described in II.4.9, p. 47, was a 
modification of Smith's technique (192). The results shown in 
Fig. 18 are for plasma samples which were treated with 
sialidase before delipidation as suggested by McDowell et al. 
(181). The duration of transfer of proteins was optimized from 
an overnight period to a six-hour period.
That a complete transfer of proteins to the immobilizing 
membrane had occurred was shown by staining the gel with 
either silver stain or CBB R-250. As a result of staining, 
either no bands or light stained bands of proteins were seen 
on the gel which demonstrates that an efficient transfer of 
proteins had taken place by this process.
Attempts to use a nitrocellulose membrane to carry out
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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TDKNTTFTCATTON OF APO F BY TMMXmOBTOTTTNG
Legend
Western blotting was carried out directly after IFF on a 
polyacrylamide gel containing 7 mol/I, urea and ampholyte of pT 
range 4-6, 5-7, in a ratio of 4/1 as described in TT.4.9, p. 
47. Lane 1, phenotype E, ,? lane 2, phenotype E, lane 3, 
phenotype E,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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the transfer of proteins from the gel were unsuccessful, 
because incomplete binding of the proteins on the nitro­
cellulose membrane occurred as evidenced by the amounts of 
proteins remaining on the gel.
TTT.3. Apol.ipppxotei.n C Tsofprms
The method used to identify apo C was identical to that 
reported above (TT.4.5, p. 44) for apo E. Both apolipoprotein 
E and C isoforms from the same delipidated VLDL sample were 
focused on the same gel using either ampholytes of pT range 4- 
6, or a mixture of 4-6 and 5-7 in a ratio of 4/1.
111.3.1. Identification of apo C isoforms
The isoelectric focusing method developed in this study 
allowed VLDL apo C to be resolved into four major peptide 
bands, which were identified by sialidase treatment (Fig. 19 
A). Densitometry of lanes 3 and 4 (Fig. 19 B) showed that 
after sialidase treatment, the apo CIIIo increased 7.8 fold, 
and was associated with a 3.6-fold decrease in the amounts of 
apo c m , ,  and a complete disappearance of apo CIII,. The 
proportion of apo CII, was slightly increased (0.4 fold), 
since this peptide does not contain sialic acid (138,186).
111.3.2. Comparison of VLDL apo C isolated by Airfuge and 
preparative ultracentrifuge:
The isoelectric focusing pattern of VLDL isolated by the 
rapid Airfuge method was similar to that of VLDL isolated by 
preparative ultracentrifugation (Fig. 20). The isoelectric
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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PTGURK 19 
TDKNTTFTCATTON OF VT.DT. APO C AND 
DKNSTTOHKTRY SCANS
Legend
(A) Isoelectric focusing pattern of VLDL Apo C. VLDL was 
isolated using the Airfuge, as described in IT.4.1,p. 38. "I'he 
PAGE gel used contained ampholyte of PI 4-6 and 7 M urea. Lane
1, carbonic anhydrase I from human erythrocytes, pi 6.6; lane
2, B-lactoglobulin, pi 5.1, and trypsin inhibitor, pi 4.6; 
lane 3, delipidated VLDL; lane 4, sialidase-treated and 
delipidated VLDL. The gel was stained with CBB R-250 as 
described in II.4.6, p.45.
(B) Densitometry scans of lanes 3 and 4 in Fig. 19A. 
Densitometry of apo C isoforms was performed at 570 nm 
(II.4.7, p. 46).
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FIG U R E 70
COMPARISON OF VT.DT, APO C ISOFORMS TSOIATED BY THE AIRFUGE AMD
PREPARATIVE (H.TRACKNTRIFUGE
T.egend
Comparison of VUDL isoelectric focusing patterns. Lane 1, 
mixture of three TEE marker proteins (starting from the 
cathode, these markers are: carbonic anhydrase I from human 
erythrocytes, pi 6.6? B-lactoglobulin, pi 5.1; and trypsin 
inhibitor, pi 4.6); lane 2, VLDL isolated by the Airfuge and 
delipidated; lane 3, VLDL isolated by preparative 
ultracentrifuge and delipidated. The PAGIF gel was prepared as 
described in II.4.4, p. 44.
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points for apo CTT and apo CTTT subspecies agreed with those 
reported by Catapano et ai. (186), but were slightly lower 
than those reported by Marcel et al. (187), and Bugugnani et 
a l . (188) ( Table XV).
TTT.3.3. Use. of ..intact _yersus_delj^idate±J^^^
VT.DT, isolated by the Airfuge method and focused with and 
without delipidation for normolipidemic plasma samples showed 
the same distribution of apo C isoforms (e.g., apo CTII^ , 10%, 
apo CTT 14%, apo CUT, 48%, apo CIII, 28%, as determined by 
densitometry). However, the delipidated VT.DL always exhibited 
better resolution of the apo C isoforms for highly lipemic 
samples. These results agreed with those previously described 
(188).
TTT.3.4- Stability study and optimization of 
solubilization conditions 
No differences in the apo C distribution were found when 
VLDL was isolated and focused immediately after the blood was 
drawn, or after storage at 4 *C for 3 months. The delipidated 
and solubilized fraction of VLDL was stable for 2 weeks at 4*C 
without any change in the percentage of apo C isoforms. In 
addition to the delipidation procedure previously described in 
TT.4.l.p. 39, an alternative method as described by McDowell 
et al. (181) using chloroform, methanol, and ether in a 
mixture of 4:2:1 v/v was evaluated. Both methods gave the same 
pattern for apo C distribution; however, for routine use we 
adopted the modified procedure (190) of Herbert et al. (191)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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TABLE XV
APPARENT TSOETECTRTC POINTS OP VT.DT. APO C
Present
method*
Catapano 
et a J.(186)
Marcel 
et a?.(187)
Bugugnani 
et a J.{188)
Apo CITT., 4.97 ± 0.03 4.93 5.09 5.1
Apo CII 4 .84 t 0.02 4.78 5.01 5.01
Apo CIII, 4.75 ± 0.02 4.72 4.91 4.92
Apo CIII.. 4.57 ± 0.03 4.54 4.80 4.84
pl values are the results of 5 replicate determinations (Mean t 
S D )  .
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since it was much more rapid. No artifacts due to delipidation 
were noticed in the present study as was reported by Bugugnani 
et a?. (188).
Incorporation of Nonidet P-40 with 7 mol/L urea and Tris- 
HCl buffer (50 mmol/L, pH 8.2) to solubilize the delipidated 
apoproteins improved the resolution of apo C isoforms, and 
greatly increased the intensity of chese bands. Similar 
results were obtained using sodium dodecyl sulfate, whereas 
Triton X-100 was less satisfactory. When 8 M urea was 
incorporated into the polyacrylamide gal, the gel had to be 
used immediately after polymerization to avoid urea 
precipitation. However, if 6 or 7 M urea was used, the 
polymerized gel could be stored tightly covered at 4*C for 3 
to 5 days.
TTT.3.5. Precision study
The within-run imprecision of the proposed method gave 
CV's that ranged between 2.7 to 11.9%, whereas the between-run 
Imprecision ranged between 4.4 to 12.2 % (Table XVI).
TIT.3.6. Apolipoprotein C distribution in VLDL from 
plasma of normal and dvslipoproteinemic 
subjects
Table XVII shows the relative percentage of apo C in VLDL 
isolated from plasma of normal, chronic renal failure, and 
hypertriglyceridemic subjects. A decrease in the ratio of apo 
CII/CIII, and an increase in the content of apo CIII, with a 
corresponding decline in apo CIII, were found in patients with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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TARTE X V I
REPRODUCTRTT.TTY STUDY FOR APO C TSOFORMS
Wjt.hln-run 
Apo C (%)
(n=9) Between-run 
Apo C (%)
(n=4 )
Mean SD CV (%) Mean SD CV (%)
CTTT,, 9.4 1.1 11.9 9.2 1.1 12.2
CTT 14.9 1.2 8 . 3 15.3 1.5 9.8
CTTT, 48.3 1.3 2.7 47.5 2.1 4.4
CTTT, 27.4 1.2 4.3 28.0 2.1 7.4
VLDL from pooled plasma was isolated using an Airfuge and apo 
C isoforms were determined.
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chronic renal failure as compared to the control subjects. 
These results agreed with those previously published (138, 
106, Isa, 210). The hypertriglyceridemic subjects showed 
similar percentages of isoforms and similar ratios of CIII, to 
CIII, and CII to CIII to normolipidemic controls (Table XVII ). 
However, one grossly hypertriglyceridemic patient with 
triglycerides of 36.2 mmol/L showed a significant elevation in 
the ratio of apo CIIIj to apo CIII, (Table XVII). It appears 
unlikely that excess sialylation of apo CIII results from 
hypertriglyceridemia per se (138). These results agreed with 
previously published data (138,188). Thus, hyper­
triglyceridemia can occur without the CIII abnormality and the 
CIII abnormality can occur without severe hyper­
triglyceridemia .
III.4. Apolipoprotein A Isoforms
Isoelectric focusing of fresh normal plasma after 
incubation with 0.05 M Tris-HCl buffer (pH 8.2) made to 
contain 0.5% Nonidet P-40, 25 mmol/L dithiothreitol, and 6 M 
urea resulted in the resolution of seven bands of pi range 
5.7-4.6 (Fig. 21). By a combination of isoelectric focusing 
and immunofixation or immunoblotting, bands 1, 2 and 3 were 
identified as apo AI, bands 5 and 6 as apo All, and band 7 as 
apo C, since it did not react with antisera to apo AI or apo 
All. Similarly, band 4 which focused at a pi of 5.37 showed no
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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FIGURE 21 
APO A VARIANTS FROM PTASMA SAMPLES
Legend
Isoelectric focusing of plasma on polyacrylamide gel 
containing 7 mol/L urea and ampholyte of pT range 4 - 6 ,  and 
5 - 7 in a ratio of 4/1. Bands are numbered from 1 to 7. Lane 
1 , are pT markers (starting from the cathode, these markers 
are; carbonic anhydrase I from human erythrocytes, pT 6.6? B-
1 actoglobulir!, pi 5.1; and trypsin inhibitor, pi 4.6). Lanes
2 to 5 are plasma samples diluted two fold with Tris-HCl 
buffer, pH 8.2, containing 6 mol/L urea, 25 mmol/L DTT, and
0.5% Nonidet P-40. The amount of plasma applied to the gel was 
2 m l (IT.4.5, p. 44).
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antigenicity to either apo AI or apo All, and it could not be 
confirmed as apo AIV due to the lack of availability of 
antiserum. Apo AI always appeared as one major band (band 2, 
Fig. 21 named apo AIo, pi 5.54), and one minor band (band 3, 
named apo AI., at a pi of 5.45).
111.4.1. Identification of apo AI
111.4.1.1. Comparison with HDL. Apo AI is the major 
protein constituent of HDL lipoprotein. HDL isolated by 
density gradient ultracentrifugation was used as a control for 
apo AI identification, and was focused on polyacrylamide gel 
together with plasma samples (Fig. 22). The two bands, one 
major the other minor, were identical for plasma samples and 
the HDL fraction, and focused at the same pi. The major band 
was identified as apo AI^ and the minor band as apo AI.,.
111.4.1.2. Immunofixation isoelectric focusing. Immuno- 
f ixation with antisera to apo AI was carried out after lEF was 
performed as described in 11.4.8, p.46. Using this method, apo 
AI in plasma samples was clearly resolved into 4 or 5 isoforms 
(Fig. 23). The bands of the apo AI isoforms shown in Fig. 23 
were identified (starting from the cathode) as apo AI^ (pi 
5.75), apo AI.i (pi 5.66), apo AIq (pi 5.54), apo AI_, (pi 
5.45), and apo Al_j (pi 5.34). The pi for apo AI isoforms 
reported here are slightly lower than those reported by Zannis 
et al. (150) and by Utermann et al. (165) (Table XVIII). The 
isoprotein apo AI.j in plasma is proapo AI, and apo AI.i seems 
likely to be a variant of proapo AI, whereas apo AI_, is a
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FIGURE 22
COMPARISON OF APO AT BETWEEN PTASMA AND HDT, SAMPLES
Legend
Isoelectric focusing pattern of apo AT. I.ane 1, mixture 
of three marker proteins (starting from the cathode these 
markers are; carbonic anhydrase T from human erythrocytes, pT 
6.6; B-lactoglobulin, pT 5.1; and trypsin inhibitor, pT 4.6), 
lane 2, plasma sample; lane 3, HDL Fraction. The PACTE gel was 
run in an ampholyte of pT range of 4-6.
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FIGURE 23
TMMUNOFIXATION ISOELECTRIC FOCUSING OF APO AT 
TN PLASMA AND HDI, SAMPLES
Legend
lEF was performed as described in Fig.21. After 
completion of IFF, the gel was cut to three sections, A, B, 
and C:
(A) Chemical fixation. Lane 1, Marker proteins as in Fig 
21; lane 2, plasma sample diluted 2 fold with Tris-HCl buffer, 
pH 8.2; lane 3, HDL diluted 2 fold. After lEF, the samples 
were fixed with trichloroacetic acid.
(B) Immunof ixation. Lane 4, plasma sample of lane 1, 
diluted 4 fold; lane 5, HDL fraction of lane 3, diluted 4 
fold; lane 6, VLDL fraction isolated by Airfuge from the same 
plasma sample as lane 2, delipidated, and solubilized with 10 
fiL of Tris-HCl buffer, pH 8.2. After lEF, these samples were 
fixed with monospecific antibody to apo AI diluted 6 fold.
(C) Immunofixation. Lane 7, plasma sample diluted 2 fold; 
lane 8, the same plasma sample as lane 1, diluted 3 fold; lane 
9, HDL sample, diluted 3 fold; lane 10, VLDL fraction isolated 
by preparative ultracentrifugation from the same plasma sample 
as lane 2, delipidated, and solubilized with 10 fih of Tris-HCl 
buffer, pH 8.2. After lEF, these samples were fixed with 
monospecific antibody to apo AI diluted 5 fold. A, B, and C 
sections of the gel were stained with CBB R-250.
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TABLE XVIII
APPARENT ISOELECTRIC POINTS OF PLASMA APO AI ISOFORMS
Isoforms Present
method*
Zannis et ai. 
(150)
Utermann et al. 
(165)
Apo AI^ 5.75 ± 0.03 5.85 -
Apo AI.i 5.66 ± 0.01 5.74 5.67
Apo Alo 5.54 ± 0.02 5.64 5.60
Apo AI_i 5.45 + 0.01 5.52 5,53
Apo AI_2 5.34 ± 0.02 5.40 5.46
“ pl values are the results of 5 replicate determinations 
(Mean ± SD).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 2 8
variant of apo Alo (145). The immunofixation method was more 
sensitive than chemical fixation (compare lanes 4 and 8 in 
Fig. 23, plasma sample after lEF with immunofixation- the 
minor bands are clearly identified, to lane 2, Fig. 23, plasma 
sample after lEF fixed chemically- the minor bands are not 
shown). Similar differences were observed for the HDL fraction 
(Fig. 23, lane 3 when it was chemically fixed and when it was 
immunofixed (Fig. 23, lanes 5 and 9)). Lanes 6 and 10 of Fig. 
23 are for the VLDL fraction isolated from the plasma sample 
of lane 2 by the Airfuge method and the preparative 
ultracentrifuge, respectively. A good resolution of the four 
apo AI bands can be seen in both VLDL fractions (lanes 6 and 
10, Fig. 23). Usually VLDL isolated from normal samples has a 
trace amount of apo AI which can be visualized as a faint band 
after lEF followed by chemical fixation and staining. By using 
the immunof ixation method developed here, five bands of apo AI 
were resolved clearly in the VLDL fraction. These bands were: 
apo AI.2,- apo AI.i,* apo AI^; apo Al.^; and apo AI., (Fig. 23).
The immunofixation method described here is very simple, 
less time consuming, and does not require the technical 
expertise compared to the method developed by Utermann et 
al.(165) and modified by Menzel et al. (167) whose immuno- 
f ixation methods to identify apo AI were very long and 
laborious. The applicability of the present method is that it 
can be used to identify patients with apo AI variants, i.e., 
apo AI„ii,u.„ (reduced HDL level); apo AId„^„, apo AIx.:bu,^ , and
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apo A T (reduced activity to T.CAT) ; or patients with
Tangier disease (deficiency of apo AT). Due to the rarity of 
such diseases, and with the limited number of samples run, no 
variants (abnormal bands) were seen.
TIT.4.1.3. Tmminoblotting for apo AT variants. The 
immunoblotting technique used to determine apo AI variants was 
the same method carried out as for apo E variants. Similar to 
immunofixation, immunoblotting of apo AI also showed five 
variants (Fig. 24) at the same pi's mentioned above (Table 
XVIII).
III.4.2. Identification of apo All
The same immunoblotting technique described for apo E and 
apo AI was used to identify apo All isoforms in plasma 
samples. One major and one or two minor isoproteins were 
detected for apo All (Pig. 25). The major isoprotein 
designated apo AIIq focused at 4.87 which coincides with band 
6 in Fig 21. The other two minor isoforms, apo All., and apo 
AII_i, were focused at pi's of 5.18 and 4.58, respectively. The 
isoelectric points obtained for apo All isoforms using the 
present lEP method was similar to those reported previously by 
Utermann et al. (165), Schmitz et al. (175), and Lackner et 
al. (211) (Table XIX). Lackner et al. (211) reported the 
presence of proapolipoprotein All (pi 6.79) and a sialic acid 
containing isoform of apo All (pi 4.20) in human plasma and 
thoracic duct lymph. In the present work, the detection of the
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PTGURF 24
TDENTTPTCATTON OP APO AT TSOFORMS BY TMMUNOBTOTTTNG
T.egend
Immunoblotting of four delipidated plasma samples (10 /iL 
each), solubilized with 100 mL of Tris-HCl buffer, pH 8.2 as 
described in TT.4.9, p. 47. The polyacrylamide gel was made to 
contain 7 mol/L urea, and ampholyte of pi range of 4-6 and 5-7 
in a ratio of 4/1. The five apo AI isoforms were clearly 
separated: apo AI.,, pl 5.75; apo AI.,, pi 5.66; apo AIq, pi 
5.54; apo AT.,, pi 5.45; and apo AI.,, pi 5.34.
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FIGURE 25
IDENTIFICATION OF APO ATI ISOFORMS BY TMMUNOBTXJTTING
T*egend
Immunoblotting as described In IT.4.9, p.47 was used to 
identify ape ATT isoforms. The polyacrylamide gel was made to 
contain 7 mol/L urea and ampholyte of pi range of 4-6. Lane 1, 
plasma sample diluted 4 fold with Tris-HCl buffer; lane 2, 
delipidated plasma sample solubilized with 80 fiL of Tris-HCl 
buffer; lane 3, plasma sample diluted 10 fold with Tris-HCl 
buffer, pH 8.2; lane 4, delipidated plasma sample as in lane 
3, solubilized with 100 ;iL Tris-HCl buffer, pH 8.2.
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1 34
TSOFORMS
Present Utermann Schmitz Lackner
method" et a? . et al. et al.
(1.65) (175) (211)
Apo ATT., 5.18 + 0.02 - 5.16 5.17
Apo ATT,, 4.87 + 0.01 4 . 88 4.89 4.90
Apo ATT , 4.58 + 0.01 - 4. 58 4.68
Apo ATT , - - 4.31 4 .42
" PT values are the results of 4 replicate determinations 
(Mean + SD).
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proapo ATT or sialylated isoforms of apo ATT were negative. 
Furthermore, when the plasma sample was treated with 
sialidase, followed by delipidation, isoelectric focusing, and 
immunoblotting, the increase in the intensity of asialo apo 
ATI isoforms was undetectable.
Apo ATT contains one cysteine residue per polypeptide 
chain, but normal apo AT does not contain cysteine (141-142). 
The presence of apo AI-ATT complex in unreduced plasma and the 
disappearance of the complex following reduction by 
dithioerythritol was described previously by Utermann et al. 
(165), who suggested that the mixed dimer of apo AT and apo 
All was linked by an interchain disulfide bridge. That 
phenomena was first described by Weisgraber et al. (212) who 
isolated and characterized a cysteine containing variant of 
the apo AT apoprotein. Furthermore, an apo ATI-apo E complex 
was also described (77,213). This mixed disulfide complex did 
not appear in the present study because a reducing agent was 
always present in the plasma sample during the procedure.
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SUMMARY AND CONCLUSIONS 
A rapid micromethod for phenotyping apo E and quantifying 
apo C in human VT.DL has been developed. This method has 
several definite advantages over- previously reported 
techniques (176-179, 186-188) including: rapid VLDL isolation 
(3 h) using an Airfuge instead of 18 h by ultracentrifugation; 
the low volume of plasma sample needed (100 pL) rather than 5 
ml. required by conventional techniques (176-179, 186-188); and 
a rapid isoelectric focusing technique (90 min) at a low 
voltage of 450 V maximum without prefocusing, compared to 
previous workers who used 250 V for 16 h (176), and 1300 V for 
90 min (177). The entire procedure including isolation of 
VLDL, casting of gel, isoelectric focusing, and staining can 
be performed the same day. This makes the technique suitable 
for routine clinical laboratory use.
The present isoelectric focusing method using a narrow pH 
gradient exhibited a high resolving power and good 
reproducibility. The pi range of ampholyte incorporated into 
the polyacrylamide gel allowed both phenotyping of apo E and 
quantifying of apo C isoforms on the same gel. The ultrathin 
flat gel used in the present isoelectric focusing system 
allowed up to ten samples to be run per gel at the same time, 
and required only 2 fiL of delipidated VLDL per sample and 4 
h staining with CBB R-250. The use of the Mini lEF Cell, where 
the gel was run inverted and in direct contact with the
136
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electrodes eliminated the need for buffers and wicks. The gel 
support film, allowed the ultrathin gel to be handled easily, 
scanned, and stored permanently without any deterioration.
Using the micromethod reported here, apo E was resolved 
into three major peptide bands, apo E,, apo E,, and apo E,, 
which focused at pi's of 6.02, 4.88, and 5.72, respectively. 
The within- and between-run CV's for the ratio of apo E,/E, 
were 6.8% and 9.75%, respectively.
The isoforms of apo C, apo CIII,,, apo CTT, apo CIII,, and 
apo CIII] focused more anodically to apo E at pi's of 4.97, 
4.84, 4.75, 4.57, respectively. As a result of scanning these 
four isoforms, the within-run CV's ranged between 2.7 and 
11.9%, and between-run CV's ranged between 4.4 and 12.2%.
The simple and rapid immunofixation method described in 
this study allowed definitive and accurate phenotyping of apo 
E and determination apo AI isoforms without any confusion with 
other bands such as proapo AI or serum amyloid A (199, 200). 
This immunofixation method can be used as a routine procedure 
for phenotyping apo E and detecting variants of apo AI.
The simplified and improved immunoblotting technique 
described in this investigation allowed complete 
immobilization of apolipoproteins from an ultrathin flat gel 
with a plastic support onto a PVDF membrane. The imrauno- 
blotting procedure permits the determination of apo E 
phenotype and detection of apo AI and apo All variants from 10 
fiL of plasma without the need for ultracentrifugation to
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isolate the VT.DT, or HDL fractions. Apol i poprotei ns E, C, and 
A were completely transferred onto the immobilizing membrane 
by this process. This assumes that if the protein was no 
longer detectable on the gel, it was actually bound to the 
PVDF membrane and none was lost into the transfer buffer or 
wi cks.
The simple method developed to detect apo AI variants 
from 5 of plasma, allowed the easy detection of five
variants (apo AI.,, apo AI.,, apo AIo, apo AI.,, and apo AI., 
which focused at pi's of 5.85, 5.74, 5.64, 5.52, and 5.40, 
respectively). Similarly, apo All showed three variants (apo 
All.,, apo AIIo, apo All., which focused at pi's of 5.18, 4.87, 
and 4.58, respectively).
Cholesterol and triglyceride assayed on VLDL fractions 
isolated by the Airfuge, and compared to that isolated by the 
ultracentrifuge, showed a good correlation (r = 0.96 for VLDL- 
C, and r = 0.997 for VLDL-TG). Furthermore, this simple method 
for the isolation of VLDL proved to be very useful for the 
determination of cholesterol in VLDL fractions from plasma 
samples with highly elevated triglyceride.
The micromethod for phenotyping apo E and quantifying apo 
C isoforms described in this study permits the technique to be 
applied to the detection of hyperlipoproteinemia type III, and 
detection of apo CXI deficiency and /or an abnormal 
distribution of VLDL apo C in hypertriglyceridemia subjects in 
a routine laboratory. Furthermore, this rapid and simple
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
1 IQ
isoelectric focusing method can be used to screen apo A and 
detect its variants without the use of ultracentrifugation.
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